

The Western Journal of Medicine

SINCE 1902

ISSN 0093-0415

44 GOUGH STREET • SAN FRANCISCO, CALIFORNIA 94103 • TELEPHONE (415) 863-5522

MALCOLM S. M. WATTS, MD, *Editor*
LLOYD H. SMITH, JR., MD, *Associate Editor*
DAVID GREER, *Managing Editor*

SALLY LINEBARGER, *Assistant to Managing Editor*
VAL BOSMOE, *Editorial Assistant*

JANICE ANDERSEN, *Copy Editor*
NANCY V. JAMES, *Advertising Production Manager*
KEVIN MCKINNEY, *Circulation Coordinator*

editorial communications to DR WATTS • business communications to MR GREER

Official Journal of the California Medical Association, the Idaho Medical Association, the Nevada State Medical Association, the New Mexico Medical Society, the Utah State Medical Association, the Washington State Medical Association and the Wyoming Medical Society.

Affiliated Scientific Societies: the Western Association of Physicians; the Western Society for Clinical Investigation; the Western Section, American Federation for Clinical Research; the Western Society for Pediatric Research; the Western Region, Society for Investigative Dermatology.

EDITORIAL BOARD

Chairman of the Board

Malcolm S. M. Watts, San Francisco, Calif

Associate Editor

Lloyd H. Smith, Jr., San Francisco, Calif

Editor for Clinical Investigation

R. Paul Robertson, Denver, Colo

Special Editor for Idaho

E. R. W. Fox, Coeur d'Alene, Idaho

Special Editor for Nevada

Owen C. Peck, Reno, Nev

Special Editor for New Mexico

Marcus J. Smith, Santa Fe, NM

Special Editor for Utah

John H. Holbrook, Salt Lake City, Utah

Special Editor for Washington

David Hopkins, Federal Way, Wash

Special Editor for Wyoming

Lloyd R. Evans, MD, Laramie, Wyo

Allergy

Harold S. Novey, Orange, Calif
Abba I. Terr, San Francisco, Calif

Anesthesiology

Ronald L. Katz, Los Angeles, Calif

Cardiac and Thoracic Surgery

John E. Connolly, Irvine, Calif
Albert Starr, Portland, Ore

Chest Diseases

Roger K. Larson, Fresno, Calif
Thomas L. Petty, Denver, Colo

Dermatology

John H. Epstein, San Francisco, Calif
George F. Odland, Seattle, Wash
Richard B. Stoughton, San Diego, Calif

Emergency Medicine

W. Richard Bukata, Van Nuys, Calif
Clark Chipman, Portland, Ore
Thomas Elmendorf, Davis, Calif

General and Family Practice

Harmon E. Holverson, Emmett, Idaho
Daniel D. Roberts, Central Point, Ore

General Surgery

John Wesley Batdorf, Las Vegas, Nev
Daniel T. Cloud, Phoenix, Ariz
Paul A. Ebert, San Francisco, Calif
Lucius D. Hill, Seattle, Wash
Frank G. Moody, Houston, Tex

Industrial Medicine and Toxicology

Thomas H. Milby, Berkeley, Calif

Internal Medicine

Robert W. Burroughs, Spokane, Wash
Theodore C. Eickhoff, Denver, Colo
Robert L. Hare, Portland, Ore
Robert H. Moser, Philadelphia, Pa
George A. Porter, Portland, Ore
Helen M. Ranney, San Diego, Calif
David D. Ulmer, Los Angeles, Calif
Edgar Wayburn, San Francisco, Calif
Ralph C. Williams, Jr, Albuquerque, NM

Neurology

Pierre M. Dreyfus, Sacramento, Calif
Philip D. Swanson, Seattle, Wash
W. C. Wiederholt, La Jolla, Calif

Neurosurgery

John R. Green, Phoenix, Ariz
Arthur A. Ward, Jr, Seattle, Wash
Charles B. Wilson, San Francisco, Calif

Nuclear Medicine

Joseph P. Kriss, Stanford, Calif

Obstetrics and Gynecology

Ralph C. Benson, Portland, Ore
Ralph W. Hale, Honolulu, Hawaii
W. LeRoy Heinrichs, Stanford, Calif
Morton A. Stenchever, Seattle, Wash

Ophthalmology

Robert S. Hepler, Los Angeles, Calif
Bruce E. Spivey, San Francisco, Calif

Orthopedics

Ernest M. Burgess, Seattle, Wash

Otolaryngology

Roger Boles, San Francisco, Calif
Mansfield F. W. Smith, San Jose, Calif

Pathology

Richard L. Kempson, Stanford, Calif

Pediatrics

Louis K. Diamond, San Francisco, Calif
William L. Nyhan, San Diego, Calif
Irving Schulman, Stanford, Calif
Arnold L. Smith, Seattle, Wash

Pharmacology

George N. Aagaard, Seattle, Wash

Physical Medicine and Rehabilitation

Glenn G. Reynolds, San Jose, Calif

Plastic Surgery

Richard P. Jobe, Los Altos, Calif

Psychiatry

Carl Eisdorfer, Bronx, NY
Alan I. Levenson, Tucson, Ariz
Helen Tausend, Beverly Hills, Calif
Joe Paul Tupin, Sacramento, Calif

Public Health

J. M. Stubblebine, Greenbrae, Calif

Radiology

M. Paul Capp, Tucson, Ariz
Melvin M. Figley, Seattle, Wash
Marshall Rowen, Orange, Calif

Urology

Richard Middleton, Salt Lake City, Utah
Thomas A. Stamey, Stanford, Calif

Consulting Editor

Medical Services and Health Care
Paul J. Sanazaro, Berkeley, Calif

ADVISORY BOARD, CLINICAL INVESTIGATION

George D. Molnar, Univ of Alberta
Murray A. Katz, Univ of Arizona
Ross E. Petty, Univ of British Columbia
Clarence A. Guenter, Univ of Calgary
M. Eric Gershwin, Univ of California, Davis

Jacob Katz, Univ of California, Irvine
Delbert A. Fisher, Univ of California, Los Angeles
Kenneth M. Moser, Univ of California, San Diego
H. Benfer Kaltreider, Univ of California, San Francisco
Alan S. Nies, Univ of Colorado

Irwin J. Schatz, Univ of Hawaii
Ernest L. Mazzaferri, Univ of Nevada
Sanford Schneider, Loma Linda Univ
Kenneth D. Gardner, Jr, Univ of New Mexico
J. David Bristow, Univ of Oregon

Robert M. McAllister, Univ of Southern California
R. Marvin Bala, Univ of Saskatchewan
Allen D. Cooper, Stanford Univ
Gerald Rothstein, Univ of Utah
R. Paul Robertson

ADVERTISING INFORMATION

Advertising Sales Representatives

EAST: Saul G. Hornik, SGH, Inc., 12 Court Street, Freehold, NJ 07728 • (201) 462-8004

MIDWEST: Donna Walters, Midwest Sales Manager, SGH, Inc., 55 East Washington Street, Suite 201, Chicago, IL 60602 • (312) 782-1100

WEST: Media Services—Lynne Jeffes, Darien DeLorenzo, 1340 Paloma Avenue, Burlingame, CA 94010 • (415) 348-7478/550-0519

CLASSIFIED: 44 Gough Street, San Francisco, CA 94103 • Tel: (415) 863-5522/863-6853

Advertisements—The journal is published the first week of the month. Advertising copy must be received not later than the first of the month preceding issue. Advertising rates will be sent on request. Acceptance of advertising is contingent upon approval by the Advertising Committee. *The journal reserves the right to reject any advertisement.*

SUBSCRIPTION INFORMATION

The subscription price per year is \$10 in the United States and Canada (US funds); \$18 in all other countries. Single copies are \$2. Address all subscription communications to THE WESTERN JOURNAL OF MEDICINE Circulation, 44 Gough Street, San Francisco, CA 94103 • Tel: (415) 863-5522.

Allow six weeks for subscriptions to begin. Past issues must be bought individually.

So long as reserve stocks are available, missing issue requests from subscribers are honored for up to six months after the issue date. Thereafter, the single copy rate of \$2.00 is applicable for each issue available.

Change of Address—Requests for change of address should give both the old and new address. Allow six weeks for changeover.

SUBMITTING MANUSCRIPTS

"Information for Authors"—A complete guide to manuscript submission and journal style is available on request and also appears in January and July.

Author Responsibility—Authors are responsible for all statements, conclusions and methods of presenting subjects. These may or may not be in harmony with the views of the editorial staff. The aim is to permit as wide a latitude as the general policy of the journal and the demands on space may permit. The right to reduce, revise or reject any manuscript is always reserved. Articles are accepted on condition that they are contributed solely to this journal.

Manuscripts—Ordinarily manuscripts should not exceed 3,000 words (less than 15 typed double-spaced pages). The original manuscript and two copies should be submitted, typed double-spaced throughout. If photographic illustrations are desired, three sets of clear, unmounted black and white glossy prints should be supplied. For line drawings, original artwork or glossy prints are acceptable. Tables should be typed on separate sheets of paper.

Clinical Investigation—Papers that authors wish considered for the Clinical Investigation section should be so designated in the transmittal letter.

PUBLISHER

Copyright 1983 by the California Medical Association • Owned and Published by the California Medical Association.

All material subject to this copyright appearing in THE WESTERN JOURNAL OF MEDICINE may be photocopied for the noncommercial purpose of scientific or educational advancement. Volumes begin with January and July.

POLICY COMMITTEE

Robert D. Burnett, MD
David B. Horner, MD
Gladden V. Elliott, MD

Richard F. Corlin, MD

Clarence S. Avery, MD
Philipp M. Lippe, MD
Malcolm S. M. Watts, MD

"Entered as second class matter at the post office in San Francisco and additional mailing offices under the Act of March 3, 1879." Acceptable for mailing at special rate of postage provided for in Section 1103, Act of October 3, 1917, authorized August 10, 1918. Publication Number 084480.

Continuing Medical Education

California, Hawaii, Nevada

Alaska • Idaho • Montana • New Mexico • Oregon • Utah • Washington • Wyoming

CALIFORNIA, HAWAII and NEVADA

This listing of continuing education programs in California, Hawaii and Nevada is supplied by the Committee on Continuing Medical Education of the California Medical Association. All courses and meetings listed have been approved for Category I credit toward the CMA Certificate in Continuing Medical Education.* To have accredited courses listed here, please send information at least two months in advance to Department of Continuing Medical Education, California Medical Association, 44 Gough St., San Francisco 94103; or phone (415) 863-5522. For a list of organizations approved for Category I credit toward the CMA Certificate in Continuing Medical Education or for more information on accreditation or certification, please write to the above address.

ANESTHESIOLOGY

November 19—**The Annual Anesthesiology Symposium.** Southern California Permanente Medical Group at South Coast Plaza Hotel, Costa Mesa. Saturday. Contact: Dana Reisman, SCPMG, 4747 Sunset Blvd., Los Angeles 90027. (213) 667-4241.

January 5-8—**Anesthesia Update.** UCSD at Hotel Del Coronado, San Diego. Thursday-Sunday. 20 hrs. \$250.

January 27-29—**22nd Annual Clinical Conference in Pediatric Anesthesiology.** Childrens Hospital of Los Angeles at Los Angeles Marriott Hotel, Los Angeles. Friday-Sunday. Contact: Wayne Herbert, MD, Program Director, 4650 Sunset Blvd., Los Angeles 90054. (213) 669-2262.

February 11-18—**4th Conference on Intensive Care Medicine.** Ohio State University, Department of Anesthesiology at Royal Hawaiian Hotel, Waikiki, HI and Hilton Hotel, Kona, HI. One week. 20 hrs. Contact: The Ohio State University Hospital, Dept. of Anesthesiology, 410 W. 10th Ave., Columbus, Ohio 43210. (614) 421-8487.

February 18-24—**12th Obstetric Anesthesia Conference.** Ohio State University Hospital, Dept. of Anesthesiology at Sheraton Waikiki Hotel, Waikiki, HI. One week. 20 hrs. Contact: The Ohio State University Hospital, Dept. of Anesthesiology, 410 W. 10th Ave., Columbus, Ohio 43210. (614) 421-8487.

CANCER

November 18—**From Fruit Flies to Onc Genes: What Developmental Biology Offers to Cancer Research.** Children's Hospital, Los Angeles. Friday. 1 hr. No fee. Contact: Stuart E. Siegel, MD, Div. of Hematology-Oncology, Children's Hospital of Los Angeles, P.O. Box 54700, Los Angeles 90054.

December 2—**One Day Colon Cancer Screening Workshop.** See Medicine, December 2.

December 4—**One Day Colon Cancer Screening Workshop.** See Medicine, December 4.

February 15-17—**Clinical Laboratory Molecular Analyses: New Strategies in Autoimmunity, Cancer, and Virology.** Scripps Clinic and Research Foundation and Mayo Clinic at Vacation

*CMA is changing CME reporting to a calendar-year basis. Continuing medical education reporting forms for the 18-month transitional period (July 1, 1982-December 31, 1983) will be sent to all CMA members in mid-January, 1984.

Village, San Diego. Wednesday-Friday. 21 hrs. \$290. Contact: Dianne Tisue, Dept. of Academic Affairs, 400S, Scripps Clinic and Research Fndn, 10666 N. Torrey Rd., La Jolla 93037.

February 24-25—**Intra-Arterial and Intracavitary Chemotherapy 1984.** UCSD at Holiday Inn at the Embarcadero, San Diego. Friday-Saturday. 14 hrs. \$250.

March 1-3—**UCLA Winter Oncology Conference.** UCLA at Miramar-Sheraton Hotel, Santa Monica. Thursday-Saturday. 18.5 hrs. \$360.

EMERGENCY MEDICINE

November 21-28—**Pediatric Emergencies.** See Pediatrics, January 21-28.

December 4-9—**Current Concepts in Emergency Care.** Institute for Emergency Medical Education and the Washington Chapter of the American College of Emergency Physicians at Maui Surf Resort, Maui, Hawaii. Sunday-Friday. 25 hrs.

(Continued on Page 620)

KEY TO ABBREVIATIONS

- CMA:** California Medical Association
Contact: Continuing Medical Education, California Medical Association, 731 Market Street, San Francisco 94103. (415) 777-2000.
- DREW:** Charles R. Drew Postgraduate Medical School
Contact: Flora Harlee-Cordett, MS, MPH, Office of Continuing Education, Charles R. Drew Postgraduate Medical School, 1621 East 120th Street, Los Angeles 90059. (213) 603-3183.
- LLU:** Loma Linda University
Contact: Varner J. Johns, Jr., MD, Associate Dean for Continuing Medical Education, Loma Linda University School of Medicine, Loma Linda 92354. (714) 796-7311, ext. 2400.
- PMC:** Pacific Medical Center
Contact: Continuing Education, Pacific Medical Center, P.O. Box 7999, San Francisco 94120. (415) 563-4321, ext. 2761.
- STAN:** Stanford University
Contact: Edward Rubenstein, MD, Associate Dean for Postgraduate Education, Stanford University School of Medicine, 300 Pasteur Drive, Stanford 94305. (415) 497-5594.
- UCD:** University of California, Davis
Contact: Ruth Ferryok, Director, Office of Continuing Medical Education, University of California, Davis, School of Medicine, Davis 95616. (916) 752-0328.
- UCI:** University of California, Irvine
Contact: E. R. Jennings, MD, Assistant Dean, University of California, Irvine, California College of Medicine, c/o UCI/CME Program, Memorial Hospital Medical Center 2801 Atlantic Ave., Long Beach 90801. (213) 595-3837.
- UCLA:** University of California, Los Angeles
Contact: Martin D. Shickman, MD, Director, Continuing Education in Medicine and the Health Sciences, P.O. Box 24902, UCLA, Los Angeles 90024. (213) 825-7241.
- UCSD:** University of California, San Diego
Contact: Office of Continuing Medical Education, University of California, San Diego, School of Medicine (M-017), La Jolla 92093. (619) 452-3708.
- UCSF:** University of California, San Francisco
Contact: David S. Gullion, MD, Director, Extended Programs in Medical Education, School of Medicine, University of California, San Francisco 94143. (415) 666-4251.
- USC:** University of Southern California
Contact: Phil R. Manning, MD, Associate Dean, Postgraduate Division, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles 90033. (213) 224-7051.

Contact: Group Travel Dept., Kailani World Travel, 4192 Meridian Ave., Bellingham, WA 93227-9951.

December 12-16—**Postgraduate Institute for Emergency Physicians, Symposium II.** UCSD. Monday-Friday. 33 hrs. \$425.

January 16-20—**Postgraduate Institute for Emergency Physicians, Symposium I.** UCSD at Holiday Inn at the Embarcadero, San Diego. Monday-Friday. 36 hrs.

January 21-28—**Pediatric Emergencies.** See Pediatrics, January 21-28.

January 30-31—**Advanced Cardiac Life Support.** Emergency Care Education Center, Inc., Emergency Department Physicians, Inc., and Greater Los Angeles Affiliate American Heart Association at Queen Mary, Long Beach. Monday-Tuesday. 16 hrs. \$225. Contact: ECEC-ACLS, 4640 Admiralty Way, Ste. 508, Marina del Rey 90291. (213) 822-1312.

January 30-February 3—**Topics in Emergency Medicine.** UCSF at Sheraton on the Wharf, San Francisco. Monday-Friday.

February 26-March 2—**Critical Care/Emergency Medicine: 1984.** UCD at Hyatt Lake Tahoe, Incline Village. Sunday-Friday.

March 4-9—**5th Annual Mammoth Mountain Emergency Medicine Ski Conference.** Medical Conferences, Inc., UCI and Orange County Emergency Department Nurses Association at Mammoth Lakes. Sunday-Friday. 20 hrs. \$325. Contact: Medical Conferences, Inc., P.O. Box 52-B, Newport Beach 92662. (714) 650-4156.

March 5-8—**22nd Annual Critical Care Medicine Symposium.** USC at MGM Grand Hotel, Las Vegas. Monday-Thursday. 25 hrs. \$395.

March 12-16—**Postgraduate Institute for Emergency Physicians, Symposium II.** UCSD at La Jolla Village Hotel, La Jolla. Monday-Friday.

March 19-20—**Advanced Cardiac Life Support.** Emergency Care Education Center, Inc., Emergency Department Physicians, Inc., and Greater Los Angeles Affiliate American Heart Association at Queen Mary, Long Beach. Monday-Tuesday. 16 hrs. \$225. Contact: ECEC-ACLS, 4640 Admiralty Way, Ste. 508, Marina del Rey 90291. (213) 822-1312.

March 30-31—**New Developments in Brain and Cardiac Resuscitation.** UCLA. Friday-Saturday. 13.5 hrs. \$180.

MEDICINE

November 18-19—**Childhood Diabetes: New Changes in Care.** See Pediatrics, November 18-19.

November 20—**Endocrinology Today.** Granada Hills Community Hospital and UCLA at Sheraton-University Hotel, North Hollywood. Sunday.

December 2—**Occupational Pulmonary Disease.** UCI. Friday.

December 2—**One Day Colon Cancer Screening Workshop.** Continuing Medical Education Associates at Holiday Inn Union Square, San Francisco. Friday. 7 hrs. \$125. Contact: J. Shiller, CME Associates, P.O. Box 84296, San Diego 92138. (619) 223-2997.

December 2—**Pulmonary Medicine for 1984.** Daniel Freeman Memorial Hospital and Daniel Freeman Marina Hospital at Daniel Freeman Memorial Hospital, Inglewood. Friday. 6 hrs. \$75. Contact: Donald A. Dennis, PhD, 333 N. Prairie, Inglewood 90301. (213) 674-7050, ext. 3427.

December 2-4—**Advances in Heart Disease.** American College of Cardiology and UCSF at Fairmont Hotel, San Francisco. Friday-Sunday. Contact: Reg. Sec., Extramural Programs Dept., ACC, 911 Old Georgetown Rd., Bethesda, MD 20814.

December 2-4—**ECG Interpretation and Arrhythmia Management.** International Medical Education Corporation at Islandia Hyatt, San Diego. Friday-Sunday. Contact: IMEC, Div. of Postgraduate and CME, 64 Inverness Dr. E., Englewood, CO 80112.

December 4—**One Day Colon Cancer Screening Workshop.**

(Continued on Page 622)

Theo-24™ (theophylline anhydrous)

Controlled-release capsules 100, 200, & 300 mg

BRIEF SUMMARY

Contraindications: Theo-24 (theophylline anhydrous) is contraindicated in patients who have shown hypersensitivity to theophylline. **Warnings:** Oral theophylline alone is not appropriate treatment for status asthmaticus which requires medication administered parenterally and close monitoring, preferably in an intensive-care setting.

Optimum therapeutic response occurs in many patients when the serum theophylline concentration is 10 to 20 mcg/ml. In other patients satisfactory results may be obtained at lower levels. In still others, adequate response may require higher levels. The physician should adjust the desired serum concentration range to the patient's requirements, keeping in mind that an increased probability of toxicity exists when levels exceed 20 mcg/ml. Measurement of serum levels is highly recommended.

In individuals in whom theophylline plasma clearance is reduced for any reason, even conventional doses may result in increased serum levels with subsequent toxicity. Reduced theophylline clearance has been documented in:

- patients with impaired renal or liver function.
- patients over 55 years of age, particularly males and those with chronic lung disease.
- patients with cardiac failure from any cause.
- neonates.

• patients taking certain drugs (macrolide antibiotics or cimetidine). Decreased clearance of theophylline may be associated with either influenza immunization or active influenza, and with other viral infections. Reduction of dosage and measurement of serum theophylline levels are especially appropriate in the above individuals.

Although the effects of theophylline are dose related, serious toxicity is not reliably preceded by less severe side effects. Ventricular arrhythmias, convulsions, or even death may appear as the first sign of toxicity without previous warning. Less serious signs of theophylline toxicity (ie, nausea and restlessness) may appear in up to 50% of these patients.

Patients who require theophylline may exhibit tachycardia due to the underlying disease process so that the cause/effect relationship to elevated serum theophylline concentrations will not be recognized.

Theophylline may cause arrhythmia or worsen preexisting arrhythmia. Any significant change in cardiac rate and/or rhythm warrants monitoring and further investigation.

In minipigs, rodents, and dogs, arrhythmia and sudden death (with histological evidence of myocardial necrosis) have been observed when theophylline and beta agonists were administered concomitantly but not when either was administered alone. The significance of these findings for human use is unknown.

Precautions: Use with caution in patients with severe cardiac disease, hypertension, acute myocardial injury, congestive heart failure, cor pulmonale, severe hypoxemia, hyperthyroidism, hepatic impairment, or alcoholism, and in the elderly (especially males) and in neonates. Particular caution should be used in administering theophylline to patients with congestive heart failure. Reduced theophylline clearance in these patients may cause serum levels to persist long after the drug is discontinued.

Individuals who are rapid metabolizers of theophylline may not be suitable candidates for once-a-day dosing. Dividing the daily dose into two doses may be indicated if symptoms of bronchospasm occur repeatedly, especially near the end of a 24-hour dosing interval.

Convulsions may occur in patients with theophylline overdosage when serum concentrations exceed 30 mcg/ml. Theophylline may lower the seizure threshold.

Theophylline should not be administered concomitantly with other xanthine medications.

Theophylline should be used cautiously in patients with a history of peptic ulcer since the disease may be exacerbated. Theophylline may occasionally act as a local irritant to the gastrointestinal tract, although gastrointestinal symptoms are more commonly mediated through the central nervous system and are usually associated with serum drug concentrations over 20 mcg/ml.

Patients should be instructed to take this medication in the morning, at approximately the same time each day, and to not exceed the prescribed dose. As with any controlled-release theophylline product the patient should alert the physician if symptoms occur repeatedly, especially near the end of a dosing interval.

Elevated serum levels of theophylline may occur in patients treated concomitantly with theophylline and cimetidine, toledromycin, or erythromycin. Therefore, such patients should be watched carefully for signs of theophylline toxicity and the dose of theophylline decreased if necessary. Increased toxicity may occur when ephedrine or other sympathomimetic drugs are given concomitantly with theophylline. The excretion of lithium carbonate is increased in patients receiving aminophylline. Aminophylline may antagonize the effects of propranolol.

Consumption of coffee, tea, cola beverages, chocolate, or acetaminophen contributes to falsely high serum theophylline levels when measured spectrophotometrically without previous isolation by chromatography.

Long-term animal studies have not been performed with theophylline to evaluate carcinogenic potential, mutagenic potential, or effect on fertility.

Pregnancy Category C. It is not known whether theophylline can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Xanthines should be given to a pregnant woman only if clearly needed.

Theophylline is secreted in breast milk and may cause adverse effects in the infant. Caution must be used when prescribing theophylline to a nursing mother, taking into account the risk/benefit of this therapy.

Safety and effectiveness in children under 12 years of age have not been established.

Adverse Reactions: Adverse reactions are usually due to overdose and are nausea, vomiting, epigastric pain, hematemesis, diarrhea, headaches, irritability, restlessness, insomnia, reflex hyperexcitability, muscle twitching, clonic and tonic generalized convulsions, coma, palpitation, tachycardia, extrasystoles, flushing, hypotension, circulatory failure, ventricular arrhythmias, tachypnea, albuminuria, microhematuria, potentiation of diuresis, hyperglycemia and inappropriate antidiuretic hormone syndrome.

Address medical inquiries to:

G.D. Searle & Co.
Medical Communications Department
Box 5110, Chicago IL 60680

3K1

SEARLE Searle & Co.
San Juan PR 00936

Dalmane® ©
flurazepam HCl/Roche

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Effective in all types of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening; in patients with recurring insomnia or poor sleeping habits; in acute or chronic medical situations requiring restful sleep. Objective sleep laboratory data have shown effectiveness for at least 28 consecutive nights of administration. Since insomnia is often transient and intermittent, prolonged administration is generally not necessary or recommended. Repeated therapy should only be undertaken with appropriate patient evaluation.

Contraindications: Known hypersensitivity to flurazepam HCl; pregnancy. Benzodiazepines may cause fetal damage when administered during pregnancy. Several studies suggest an increased risk of congenital malformations associated with benzodiazepine use during the first trimester. Warn patients of the potential risks to the fetus should the possibility of becoming pregnant exist while receiving flurazepam. Instruct patient to discontinue drug prior to becoming pregnant. Consider the possibility of pregnancy prior to instituting therapy.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. An additive effect may occur if alcohol is consumed the day following use for nighttime sedation. This potential may exist for several days following discontinuation. Caution against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Potential impairment of performance of such activities may occur the day following ingestion. Not recommended for use in persons under 15 years of age. Though physical and psychological dependence have not been reported on recommended doses, abrupt discontinuation should be avoided with gradual tapering of dosage for those patients on medication for a prolonged period of time. Use caution in administering to addiction-prone individuals or those who might increase dosage.

Precautions: In elderly and debilitated patients, it is recommended that the dosage be limited to 15 mg to reduce risk of oversedation, dizziness, confusion and/or ataxia. Consider potential additive effects with other hypnotics or CNS depressants. Employ usual precautions in severely depressed patients, or in those with latent depression or suicidal tendencies, or in those with impaired renal or hepatic function.

Adverse Reactions: Dizziness, drowsiness, lightheadedness, staggering, ataxia and falling have occurred, particularly in elderly or debilitated patients. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdosage, have been reported. Also reported: headache, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, GI pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and GU complaints. There have also been rare occurrences of leukopenia, granulocytopenia, sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations, and elevated SGOT, SGPT, total and direct bilirubins, and alkaline phosphatase; and paradoxical reactions, e.g., excitement, stimulation and hyperactivity.

Dosage: Individualize for maximum beneficial effect. *Adults:* 30 mg usual dosage; 15 mg may suffice in some patients. *Elderly or debilitated patients:* 15 mg recommended initially until response is determined.

Supplied: Capsules containing 15 mg or 30 mg flurazepam HCl.



Roche Products Inc.
Manati, Puerto Rico 00701

Continuing Medical Education Associates at Vacation Village Hotel, San Diego. Sunday. 7 hrs. \$125. Contact: J. Shiller, CME Associates, P.O. Box 84296, San Diego 92138. (619) 223-2997.

December 7-10—**International Symposium on Basic Mechanisms of Epilepsies.** See Of Interest To All Physicians, December 7-10.

December 9-10—**9th Annual Allergy-Immunology Symposium.** Southern California Permanente Medical Group at Los Angeles Hilton. Friday-Saturday. Contact: Lilia Guerrero, SCPMG, 4747 Sunset Blvd., Los Angeles 90027. (213) 667-4241.

December 9-10—**Allergy and Asthma: The 5th Annual University of California Course on Allergic and Asthmatic Diseases with Doctors Hyman Chai and Martin Valentine.** UCD at Capitol Plaza, Sacramento. Friday-Saturday. \$195.

December 14—**Complications of Dialysis: Their Diagnosis and Management.** LLU. Wednesday. \$50.

December 27-29—**ABC's of Allergy-Immunology.** Hawaii Chapter of American Academy of Family Practice, Hawaii Medical Association and Symposium Maui, Inc. at Royal Lahaina Resort, Kaanapali, Maui, Hawaii. Tuesday-Thursday. Contact: Joe Harrison, MD, Symposium Maui, Inc., P.O. Box 10185, Lahaina, Maui, HI 96761. (808) 661-8032.

January 6-8—**Western Section Meeting—American Laryngological, Rhinological and Otological (Trillogical) Society** at Marriott Biltmore, Santa Barbara. Friday-Sunday. Contact: Joseph R. DiBartolomeo, MD, Secretary, 2420 Castillo St., Santa Barbara 93105.

January 11—**Diabetic Therapy in 1984.** LLU. Wednesday. \$50.

January 16-20—**2nd Biannual Gastrointestinal and Hepatic Diseases Conference.** Honolulu Medical Group Research and Education Foundation at Mauna Kea Beach Hotel, Hawaii. Monday-Friday. 20 hrs. Contact: Yvonne Brewer, MPH, Education Director, HMGREF, 550 Beretania St., Honolulu, HI 96813. (808) 537-2211, ext. 751.

January 19-21—**American Society for Gastrointestinal Endoscopy Meeting** at San Francisco. Thursday-Saturday. 16 hrs. Contact: Mr. William T. Maloney, Executive Director, ASGE/PG, 13 Elm St., Manchester, MA 01944. (617) 927-8330.

January 19-21—**Dual Brain.** UCLA. Thursday-Saturday. 26 hrs. \$160.

January 20-22—**Practical Dermatology and Dermatologic Office Procedures for the Primary Care Physician.** See Of Interest To All Physicians, January 20-22.

January 23-27—**8th Annual Hawaii Echocardiography Conference.** Honolulu Medical Group Research and Education Foundation at Kahala Hilton Hotel, Honolulu. Monday-Friday. Contact: Yvonne Brewer, MPH, Education Director, HMGREF, 550 S. Beretania St., Honolulu, HI 96813. (808) 517-2211, ext. 751.

January 26-28—**Alzheimer's Disease: Toward Clinical Management.** Annenberg Center for Health Sciences, Rancho Mirage. Thursday-Saturday. Contact: Annenberg Center for Health Sciences-A, Eisenhower Medical Center, 39000 Bob Hope Dr., Rancho Mirage 92270. (619) 340-3911.

January 30-February 2—**Current Concepts in Cardiology.** American College of Cardiology and Coronado Hospital at Hotel Del Coronado, Coronado. Monday-Thursday. Contact: Registration Secretary, Extramural Programs Dept., ACC, 911 Old Georgetown Rd., Bethesda, MD 20814.

February 2-4—**Recent Advances in Geriatric Medicine: A New Look at Caring for the Elderly.** UCSD at Holiday Inn, San Diego. Thursday-Saturday.

February 3-4—**Current Problems in Clinical Endocrinology.** Scripps Clinic and Research Foundation, La Jolla. Friday-Saturday. Contact: Dianne Tisue, Conference Coordinator, Scripps Clinic and Research Foundation, 10666 N. Torrey Pines Rd., La Jolla 92037. (714) 455-9100.

February 8—**Diagnosis of Acute and Chronic Abdominal Pain.** LLU. Wednesday. 4 hrs. \$50.


(Continued on Page 624)

(Continued from Page 622)

- February 8-10—**17th Annual Recent Advances in Neurology.** UCSF at Fairmont, San Francisco. Wednesday-Friday.
- February 10-12—**ECG Interpretation and Arrhythmia Management.** International Medical Education Corporation at Sheraton Hotel, Santa Barbara. Friday-Sunday. Contact: IMEC, Div. of Postgraduate and CME, 64 Inverness Dr. E., Englewood, CO 80112.
- February 10-18—**Topics in Internal Medicine.** UCSD. One week.
- February 13-24—**Intensive Residency in Occupational Medicine.** UCSF. 2 weeks. 65.5 hrs. \$1,000.
- February 16-18—**Consultative Cardiology: Update in Diagnostic and Therapeutic Techniques.** American College of Cardiology and Orange Coast Heart Institute, Hoag Memorial Hospital Presby. at Newport Beach Marriott Hotel and Tennis Club, Newport Beach. Thursday-Saturday. Contact: Registration Secretary, Extramural Programs Department, ACC, 911 Old Georgetown Rd., Bethesda, MD 20814.
- February 18—**Infectious Disease.** UCD at Red Lion Inn, Sacramento. Saturday.
- February 23-26—**State of the Art in Neurosciences.** Federation of Western Societies of Neurological Science at Silverado Country Club, Napa. Thursday-Sunday. 18 hrs. Contact: FWSNS, 525 Hurlingham Ave., San Mateo 94402. (415) 340-9084.
- February 29-March 3—**7th Annual Course: Immunology and Clinical Practice of Allergy.** UCSD. Wednesday-Saturday. 20 hrs.
- March 2—**10th Annual Diabetes Program.** UCD at Sacramento Inn, Sacramento. Friday.
- March 2-4—**Cardiovascular Disease: Non-Invasive Diagnostic Methods and Cardiac Rehabilitation.** International Medical Education Corporation at Islandia Hyatt, San Diego. Friday-Sunday. Contact: IMEC, Div. of Postgraduate and CME, 64 Inverness Dr. E., Englewood, CO 80112.
- March 4-7—**Basic Cardiology for the Practicing Physician.** UCSF at Lake Tahoe. Sunday-Wednesday. \$15 hrs. \$225.
- March 7-10—**Office Endocrinology.** UCSF at Hyatt Lake Tahoe. Wednesday-Saturday. 15 hrs. \$225.
- March 8-10—**1984 International Symposium on Viral Hepatitis.** UCSF at Hilton, San Francisco. Thursday-Saturday.
- March 8-10—**Advanced Nephrology and Hypertension: Nephrology for the Consultant.** Annenberg Center for Health Sciences and UCSD at Annenberg Center, Rancho Mirage. Thursday-Saturday. 18 hrs. Contact: Annenberg Center for Health Sciences, Eisenhower Medical Center, 39000 Bob Hope Dr., Rancho Mirage 92270. (619) 340-3911, ext. 1661.
- March 14—**Arthritis of the Single Joint.** LLU. Wednesday. \$50.
- March 15-16—**New Concepts in Hemophilia.** UCD at Capitol Plaza Holiday Inn, Sacramento. Thursday-Friday.
- March 15-17—**Frontiers in Rheumatology.** Annenberg Center for Health Sciences of the Eisenhower Medical Center, Rancho Mirage. Thursday-Saturday. 16 hrs. Contact: Annenberg Center for Health Sciences-A, Eisenhower Medical Center, 39000 Bob Hope Dr., Rancho Mirage 92270. (800) 621-7322.
- March 16-18—**Advanced Cardiovascular Diagnostic, Rehabilitation and Patient Follow-up Methods.** International Medical Education Corporation at St. Francis Hotel, San Francisco. Friday-Sunday. Contact: IMEC, Div. of Postgraduate and CME, 64 Inverness Dr. E., Englewood, CO 80112.
- March 16-18—**ECG Interpretation and Arrhythmia Management.** International Medical Education Corporation at Marriott Hotel, Palm Springs. Friday-Sunday. Contact: IMEC, Div. of Postgraduate and CME, 64 Inverness Dr. E., Englewood, CO 80112.
- March 29-30—**1984 Updates: Medical and Behavioral Treatment.** See Of Interest To All Physicians, March 29-30.

(Continued on Page 629)

SPECIFY



Each capsule contains 5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide

Please consult complete prescribing information, a summary of which follows:

Indications: Based on a review of this drug by the National Academy of Sciences—National Research Council and/or other information, FDA has classified the indications as follows: "Possibly" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation.

Contraindications: Glaucoma; prostatic hypertrophy, benign bladder neck obstruction; hypersensitivity to chlordiazepoxide HCl and/or clidinium Br.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants, and against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Physical and psychological dependence rarely reported on recommended doses, but use caution in administering Librium® (chlordiazepoxide HCl/Roche) to known addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions) reported following discontinuation of the drug.

Use in Pregnancy: Use of minor tranquilizers during first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy. Advise patients to discuss therapy if they intend to or do become pregnant.

As with all anticholinergics, inhibition of lactation may occur. **Precautions:** In elderly and debilitated, limit dosage to smallest effective amount to preclude ataxia, oversedation, confusion (no more than 2 capsules/day initially; increase gradually as needed and tolerated). Though generally not recommended, if combination therapy with other psychotropics seems indicated, carefully consider pharmacology of agents, particularly potentiating drugs such as MAO inhibitors, phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Paradoxical reactions reported in psychiatric patients. Employ usual precautions in treating anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation reported very rarely in patients receiving the drug and oral anticoagulants; causal relationship not established.

Adverse Reactions: No side effects or manifestations not seen with either compound alone reported with Librax. When chlordiazepoxide HCl is used alone, drowsiness, ataxia, confusion may occur, especially in elderly and debilitated; avoidable in most cases by proper dosage adjustment, but also occasionally observed at lower dosage ranges. Syncope reported in a few instances. Also encountered: isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido—all infrequent, generally controlled with dosage reduction; changes in EEG patterns may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice, hepatic dysfunction reported occasionally with chlordiazepoxide HCl, making periodic blood counts and liver function tests advisable during protracted therapy. Adverse effects reported with Librax typical of anticholinergic agents, i.e., dryness of mouth, blurring of vision, urinary hesitancy, constipation. Constipation has occurred most often when Librax therapy is combined with other spasmolytics and/or low residue diets.



Roche Products Inc.
Manati, Puerto Rico 00701

(Continued from Page 621)

March 31-April 7—**Diagnostic and Therapeutic Skills.** USC at Mauna Kea Hotel, Mauna Kea, HI. One week.

OBSTETRICS AND GYNECOLOGY

December 2-4—**Current Issues in Perinatal Medicine.** UCI and Memorial Hospital Medical Center at Marriott's Rancho Las Palmas Resort, Rancho Mirage. Friday-Sunday. 15 hrs.

December 9-10—**Genetics, Birth Defects and the High Risk Patient.** UCD at Capitol Plaza, Sacramento. Friday-Saturday.

January 9-10—**Advanced Fetal Heart Rate Monitoring.** Memorial Hospital Medical Center and UCI at Hyatt Regency, Long Beach. Monday-Tuesday. 10 hrs. Contact: Memorial Hospital Medical Center, Asst. Director, Center for Health Education, 2801 Atlantic Ave., Long Beach 90801-1428.

January 13-14—**Cardiac Disease in Pregnancy.** USC at Beverly Hilton Hotel, Beverly Hills. Friday-Saturday.

February 4-10—**Perinatal Medicine.** USC at Royal Lahaina Hotel, Maui. One week. 23 hrs. \$450.

February 5-10—**Ob/Gyn Update: 1984.** UCD at Hyatt Lake Tahoe, Incline Village. Sunday-Friday.

February 11-12—**Los Angeles Ob/Gyn Forum.** Los Angeles Ob/Gyn Society at Beverly Hilton Hotel, Beverly Hills. Saturday-Sunday. 10 hrs. \$80. Contact: Director of Medical Education, LA Ob/Gyn Soc., 5820 Wilshire Blvd., #500, Los Angeles 90036. (213) 937-5514.

February 13-17—**39th Annual Postgraduate Assembly.** Obstetrical and Gynecological Assembly of Southern California at Beverly Hilton Hotel, Beverly Hills. Monday-Friday. 28 hrs. \$375. Contact: Director of Medical Education, Ob/Gyn Assembly of S. California, 5820 Wilshire Blvd., #500, Los Angeles 90036. (213) 937-5514.

February 16-18—**Advanced Fetal Heart Rate Monitoring.** Memorial Hospital Medical Center and UCI at Sheraton-Waikiki, Oahu. Thursday-Saturday. 10 hrs. Contact: Asst. Dir., Center for Health Education, 2801 Atlantic Ave., Long Beach 90801-1428.

February 25—**Office Gynecology.** UCLA. Saturday.

March 14-17—**Contemporary Obstetrics: A Guide to the Physician in Practice.** March of Dimes Birth Defects Foundation, Orange County Chapter, UCI and St. Joseph Hospital at Disneyland Hotel, Anaheim. Wednesday-Saturday. 21.5 hrs. \$210. Contact: Michelle S. Wampler, March of Dimes Birth Defects Foundation, Orange County Chapter, Rea Community Center, 661 Hamilton, #650, Costa Mesa 92627-2690.

March 23-25—**Gynecologic Surgery with Emphasis on Gynecologic Urology.** Memorial Hospital Medical Center and UCI at Hilton Riviera, Palm Springs. Friday-Sunday. 15 hrs. Contact: Asst. Dir., Center for Health Ed., 2801 Atlantic Ave., Long Beach 90801-1428.

PEDIATRICS

November 18-19—**Childhood Diabetes: New Changes in Care.** UCD at Woodlake Inn, Sacramento. Friday-Saturday. \$95.

November 18-21—**5th Annual Las Vegas Seminar—Pediatrics Update.** American Academy of Pediatrics at Caesar's Palace, Las Vegas. Friday-Monday. Contact: Eve Black, Executive Secretary, P.O. Box 2134, Inglewood 90305. (213) 757-1198.

December 3—**Management of the Critically Ill Child.** California Chapter 1 of American Academy of Pediatrics at Holiday Inn, San Francisco. Saturday. Contact: Beverly Busher, 1125 A St., Ste. 210, San Rafael 94901. (415) 459-4775.

January 11—**23rd Annual Parmelee Memorial Lecture.** Los Angeles Pediatric Society at Los Angeles. Wednesday. Contact: Eve Black, Executive Secretary, P.O. Box 2022, Inglewood 90305. (213) 757-1198.

January 21-28—**Pediatric Emergencies.** UCSD at Kona, Hawaii. One week. 21 hrs. \$335.

Candidates for nutritional therapy...

10,000,000 alcoholics. Ethanol may produce many effects that together bring about nutritional deficiencies, so that alcoholism affects nutrition at many levels.*



Berocca Plus. A balanced formula for prophylactic or therapeutic nutritional supplementation. Berocca Plus Tablets provide: therapeutic levels of ascorbic acid and B-complex vitamins; supplemental levels of biotin, vitamins A and E, and five important minerals (iron, chromium, manganese, copper and zinc); plus magnesium. Berocca Plus is not intended for the treatment of specific vitamin and/or mineral deficiencies.

...candidates
for
Berocca[®] Plus TABLETS
THE MULTIVITAMIN/MINERAL FORMULATION

*Shaw S. Lieber CS: Nutrition and alcoholism, chap. 40, in *Modern Nutrition in Health and Disease*, edited by Goodhart RS, Shils ME: Philadelphia, Lea & Febiger, 1980, pp. 1220, 1237.


Please see summary of product information on reverse page.

Copyright © 1983 by Hoffmann-La Roche Inc. All rights reserved.



Rx ONLY **Berocca®
Plus TABLETS**
THE MULTIVITAMIN/MINERAL FORMULATION

also available as
Rx ONLY **Berocca® TABLETS**



Before prescribing, please consult complete product information, a summary of which follows:

Each Berocca® tablet contains: 500 mg vitamin C (ascorbic acid), 15 mg vitamin B₁ (as thiamine mononitrate), 15 mg vitamin B₂ (riboflavin), 100 mg niacin (as niacinamide), 4 mg vitamin B₆ (as pyridoxine HCl), 18 mg pantothenic acid (as calcium D-pantothenate), 0.5 mg folic acid, 5 mcg vitamin B₁₂ (cyanocobalamin). Each Berocca® Plus tablet contains: 5000 IU vitamin A (as vitamin A acetate), 30 IU vitamin E (as *d,l*-alpha-tocopheryl acetate), 500 mg vitamin C (ascorbic acid), 20 mg vitamin B₁ (as thiamine mononitrate), 20 mg vitamin B₂ (riboflavin), 100 mg niacin (as niacinamide), 25 mg vitamin B₆ (as pyridoxine HCl), 0.15 mg biotin, 25 mg pantothenic acid (as calcium pantothenate), 0.8 mg folic acid, 50 mcg vitamin B₁₂ (cyanocobalamin), 27 mg iron (as ferrous fumarate), 0.1 mg chromium (as chromium nitrate), 50 mg magnesium (as magnesium oxide), 5 mg manganese (as manganese dioxide), 3 mg copper (as cupric oxide), 22.5 mg zinc (as zinc oxide).

INDICATIONS: Berocca—Supportive nutritional supplementation in which water-soluble vitamins are required prophylactically or therapeutically, including conditions causing depletion, or reduced absorption or bioavailability of water-soluble vitamins, conditions resulting in increased needs for water-soluble vitamins. Berocca Plus—Prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions, including conditions causing depletion, or reduced absorption or bioavailability of essential vitamins and minerals, certain conditions resulting from severe B-vitamin or ascorbic acid deficiency, or conditions resulting in increased needs for essential vitamins and minerals.

CONTRAINDICATIONS: Hypersensitivity to any component.

WARNINGS: Not for pernicious anemia or other megaloblastic anemias where vitamin B₁₂ is deficient. Neurologic involvement may develop or progress, despite temporary remission of anemia, in patients with vitamin B₁₂ deficiency who receive supplemental folic acid and who are inadequately treated with B₁₂.

PRECAUTIONS: *General:* Certain conditions may require additional nutritional supplementation. During pregnancy, vitamin D and calcium supplementation may be required with Berocca Plus or supplementation with fat-soluble vitamins and minerals may be required with Berocca. Not intended for treatment of severe specific deficiencies. *Information for the Patient:* Toxic reactions have been reported with injudicious use of certain vitamins and minerals. Urge patients to follow specific dosage instructions. Keep out of reach of children. *Drug and Treatment Interactions:* As little as 5 mg pyridoxine daily can decrease efficacy of levodopa in treatment of parkinsonism. Not recommended for patients undergoing such therapy.

ADVERSE REACTIONS: Have been reported with specific vitamins and minerals, but generally at levels substantially higher than those in Berocca and Berocca Plus. Allergic and idiosyncratic reactions are possible at lower levels. Iron, even at recommended levels, has been associated with GI intolerance in some patients.

DOSAGE AND ADMINISTRATION: Usual adult dosage: one tablet daily. Available on prescription only (Berocca Plus is not recommended for children).

HOW SUPPLIED: Berocca—Light green, capsule-shaped tablets—bottles of 100 and 500. Berocca Plus—Golden yellow, capsule-shaped tablets—bottles of 100.



ROCHE LABORATORIES
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

January 27-29—**22nd Annual Clinical Conference in Pediatric Anesthesiology.** See Anesthesiology, January 27-29.

March 15-18—**Combined Southern California Pediatric Postgraduate Meeting.** American Academy of Pediatrics, California Chapter 2 at Palm Springs. Thursday-Sunday. Contact: Eve Black, Exec. Sec., P.O. Box 2134, Inglewood 90305. (213) 757-1198.

March 24-25—**Pediatric Orthopedics.** UCLA. Saturday-Sunday.

PSYCHIATRY

November 18-19—**Family Therapy Training and Supervision: Creating Contexts of Competence.** Mental Research Institute, Palo Alto. Friday-Saturday. 10 hrs. \$100. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

December 19-24—**Conference on Psychiatric Care of the Injured Worker.** Pacific Medical Center at SS Constitution, San Francisco to Honolulu. Monday-Saturday. 30 hrs. \$465. Contact: Robert B. Cahan, MA, MD, Program Director, 2340 Sutter St., Ste. 308, San Francisco 94115. (415) 587-7973.

January 14—**The Interactional View.** Mental Research Institute, Palo Alto. Saturday. 6 hrs. \$70. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

January 16-19—**Family Crises: Intervention Strategies.** Mental Research Institute, Palo Alto. Monday-Thursday. 12 hrs. \$150. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

January 21—**Developing a Personal Evolving Model of Therapy: What to Do After the Music of Formal Training Stops.** Mental Research Institute, Palo Alto. Saturday. 6 hrs. \$75. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

January 22-26—**Mental Research Institute Winter Seminar at Mental Research Institute, Palo Alto.** Sunday-Thursday. 27 hrs. \$270. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

January 25-29—**Intensive Review of Psychiatry and Neurology.** USC at The Palm Springs Racquet Club, Palm Springs. Wednesday-Sunday.

January 28—**Treating Depression in a Marital Context.** Mental Research Institute, Palo Alto. Saturday. 6 hrs. \$60. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

January 29-February 3—**10th Annual Midwinter Program in Continuing Education for Psychiatrists.** UCD at Hyatt Lake Tahoe, Incline Village. Sunday-Friday.

February 6-10—**Couple and Family Therapy: Conflict and Change.** Mental Research Institute, Palo Alto. Monday-Friday. 15 hrs. \$150. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

February 11—**The Interactional Treatment of Eating Disorders.** Mental Research Institute, Palo Alto. Saturday. 7 hrs. \$95. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

February 17-18—**Family Therapy and Supervision: Creating Contexts of Competence.** Mental Research Institute, Palo Alto. Friday-Saturday. 10 hrs. \$100. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

February 22-24—**Sexually Traumatized Adults, Children and Adolescents.** Mental Research Institute, Palo Alto. Wednesday-Friday. 9 hrs. \$90. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

February 25—**Issues in Interactional Theory and Research.** Mental Research Institute, Palo Alto. Saturday. 6 hrs. \$75. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.

March 14-18—**The Development of the Able Mind Revisited.** Southern California Neuropsychiatric Institute at La Quinta Hotel Golf and Tennis Resort, La Quinta. Wednesday-Sunday. 24 hrs. Contact: Gail Waldron, MD, Program Director, SCNI, 6794 La Jolla Blvd., La Jolla 92037. (619) 454-2102.

(Continued on Page 632)

March 29-30—1984 Updates: Medical and Behavioral Treatment. See Of Interest To All Physicians, March 29-30.

RADIOLOGY AND PATHOLOGY

December 4-9—**Diagnostic Radiology Seminar.** UCSF at Hyatt Regency Hotel, Maui. Sunday-Friday. 25 hrs. \$400.

December 10—**Chest Imaging Update 1983.** Cedars-Sinai Medical Center, Los Angeles. Saturday. 6½ hrs. \$90. Contact: Lore Kahane, Room 2049, Cedars-Sinai Medical Center, Box 48750, Los Angeles 90048. (213) 855-5547.

January 9-14—**NMR, CT and Interventional Radiology.** UCSF at Fairmont Hotel and Tower, San Francisco. Monday-Saturday. 29½ hrs. \$400.

January 16-19—**Chest Radiology 1984.** UCSD. Monday-Thursday. 24 hrs. \$350.

January 23-27—**Tumorous Conditions of the Bones and Soft Tissues.** American Society of Clinical Pathologists at Town and Country Hotel, San Diego. Monday-Friday. 38.5 hrs. \$650. Contact: ASCP, Regional Ed. Activities, 2100 W. Harrison St., Chicago 60612. (312) 738-1336, ext. 129.

January 29-February 3—**6th Annual Winter Conference in the High Sierras.** American College of Medical Imaging at Sahara Tahoe Hotel, Lake Tahoe. Saturday-Thursday. 25 hrs. Contact: ACMI, P.O. Box 27188, Los Angeles 90027. (213) 275-1393.

February 1-3—**11th Annual Course in Genitourinary Pathology.** UCI and Memorial Medical Center of Long Beach, Long Beach. Wednesday-Friday. 24 hrs.

February 10-12—**Recent Advances in Noninvasive Cardiac Imaging: Application in the Diagnosis and Management of Ischemic Heart Disease.** American College of Cardiology and Cedars-Sinai Medical Center at The Century Plaza Hotel, Los Angeles. Friday-Sunday. Contact: Registration Secretary, Extramural Programs Dept., ACC, 911 Old Georgetown Rd., Bethesda, MD 20814.

February 29-March 2—**4th Annual Current Approaches to Radiation Oncology, Biology, and Physics.** UCSF. Wednesday-Sunday.

March 12-16—**International Academy of Pathology Annual Meeting.** United States-Canadian Division of the International Academy of Pathology at San Francisco Hilton. Monday-Friday. Contact: Dr. Nathan Kaufman, Sec.-Treas., USCDIAP, 1003 Chafee Ave., Augusta, GA 30904. (404) 724-2973.

SURGERY

November 18-20—**Mitral Valve: A Workshop on Reconstructive Techniques.** Scripps Clinic and Research Foundation, La Jolla. Friday-Sunday. 17 hrs. \$350. Contact: Dianne Tisue, Dept. of Academic Affairs, Box 400S, Scripps Clinic and Research Foundation, 10666 N. Torrey Rd., La Jolla 92037.

December 3—**Update on Eyelid and Orbital Surgery.** Jules Stein Eye Institute, Los Angeles. Saturday. 8 hrs. \$125. Contact: Lu Hendricks, Academic Program Admin., JSEI, UCLA School of Medicine, Center for Health Sciences, Los Angeles 90024.

December 5-9—**Advanced Microsurgery Training Workshop.** UCSD. Monday-Friday. 34 hrs. \$1,200.

December 8-9—**Current Management of Common Retinal Disorders.** UCSF at Hyatt Regency, San Francisco. Thursday-Friday.

December 8-9—**Current Developments in Ophthalmology.** USC and Estelle Doheny Eye Foundation at Palm Springs. Thursday-Friday. Contact: USC/EDEF, 1355 San Pablo St., Los Angeles 90033. (213) 224-7752.

December 10—**UCLA Department of Ophthalmology Association Clinical Meeting.** Jules Stein Eye Institute, Los Angeles. Saturday. 6 hrs. \$15. Contact: Lu Hendricks, Academic Program Admin., Jules Stein Eye Institute, UCLA School of Medicine, Center for Health Sciences, Los Angeles 90024.

(Continued on Page 636)

References:

1. Stone PH, Turi ZG, Muller JE: Efficacy of nifedipine therapy for refractory angina pectoris. *Am Heart J* 104:672-681, September 1982.
2. Antman E, Muller J, Goldberg S, et al: Nifedipine therapy for coronary-artery spasm: Experience in 127 patients. *N Engl J Med* 302:1269-1273, June 5, 1980.

BRIEF SUMMARY

PROCARDIA® (nifedipine) CAPSULES

For Oral Use

INDICATIONS AND USAGE: I. **Vasospastic Angina:** PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers.

II. **Chronic Stable Angina (Classical Effort-Associated Angina):** PROCARDIA is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents.

In chronic stable angina (effort-associated angina) PROCARDIA has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in those patients are incomplete.

Controlled studies in small numbers of patients suggest concomitant use of PROCARDIA and beta blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See Warnings.)

CONTRAINDICATIONS:

Known hypersensitivity reaction to PROCARDIA.
WARNINGS: Excessive Hypotension: Although in most patients, the hypotensive effect of PROCARDIA is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension. These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.

Severe hypotension and/or increased fluid volume requirements have been reported in patients receiving PROCARDIA together with a beta blocking agent who underwent coronary artery bypass surgery using high dose fentanyl anesthesia. The interaction with high dose fentanyl appears to be due to the combination of PROCARDIA and a beta blocker, but the possibility that it may occur with PROCARDIA alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. In PROCARDIA treated patients where surgery using high dose fentanyl anesthesia is contemplated, the physician should be aware of these potential problems and, if the patient's condition permits, sufficient time (at least 36 hours) should be allowed for PROCARDIA to be washed out of the body prior to surgery.

Increased Angina: Occasional patients have developed well documented increased frequency, duration or severity of angina on starting PROCARDIA or at the time of dosage increases. The mechanism of this response is not established but could result from decreased coronary perfusion associated with decreased diastolic pressure with increased heart rate, or from increased demand resulting from increased heart rate alone.

Beta Blocker Withdrawal: Patients recently withdrawn from beta blockers may develop a withdrawal syndrome with increased angina, probably related to increased sensitivity to catecholamines. Initiation of PROCARDIA treatment will not prevent this occurrence and might be expected to exacerbate it by provoking reflex catecholamine release. There have been occasional reports of increased angina in a setting of beta blocker withdrawal and PROCARDIA initiation. It is important to taper beta blockers if possible, rather than stopping them abruptly before beginning PROCARDIA.

Congestive Heart Failure: Rarely, patients, usually receiving a beta blocker, have developed heart failure after beginning PROCARDIA. Patients with tight aortic stenosis may be at greater risk for such an event.

PRECAUTIONS: General: Hypotension: Because PROCARDIA decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of PROCARDIA is suggested. Close observation is especially recommended for patients already taking medications that are known to lower blood pressure. (See Warnings.)

Peripheral edema: Mild to moderate peripheral edema, typically associated with arterial vasodilation and not due to left ventricular dysfunction, occurs in about one in ten patients treated with PROCARDIA. This edema occurs primarily in the lower extremities and usually responds to diuretic therapy. With patients whose angina is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.

Drug Interactions: Beta-adrenergic blocking agents: (See Indications and Warnings.) Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of PROCARDIA and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.

Long-acting nitrates: PROCARDIA may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

Digitalis: Administration of PROCARDIA with digoxin increased digoxin levels in nine of twelve normal volunteers. The average increase was 45%. Another investigator found no increase in digoxin levels in thirteen patients with coronary artery disease. In an uncontrolled study of over two hundred patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed. Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing PROCARDIA to avoid possible over- or under-digitalization.

Carcinogenesis, mutagenesis, impairment of fertility: When given to rats prior to mating, nifedipine caused reduced fertility at a dose approximately 30 times the maximum recommended human dose.

Pregnancy: Category C. Please see full prescribing information with reference to teratogenicity in rats, embryotoxicity in rats, mice and rabbits, and abnormalities in monkeys.

ADVERSE REACTIONS: The most common adverse events include dizziness or light-headedness, peripheral edema, nausea, weakness, headache and flushing each occurring in about 10% of patients, transient hypotension in about 5%, palpitation in about 2% and syncope in about 0.5%. Syncopal episodes did not recur with reduction in the dose of PROCARDIA or concomitant antianginal medication. Additionally, the following have been reported: muscle cramps, nervousness, dyspnea, nasal and chest congestion, diarrhea, constipation, inflammation, joint stiffness, shakiness, sleep disturbances, blurred vision, difficulties in balance, dermatitis, pruritus, urticaria, fever, sweating, chills, and sexual difficulties. Very rarely, introduction of PROCARDIA therapy was associated with an increase in anginal pain, possibly due to associated hypotension.

In addition, more serious adverse events were observed, not readily distinguishable from the natural history of the disease in these patients. It remains possible, however, that some or many of these events were drug related. Myocardial infarction occurred in about 4% of patients and congestive heart failure or pulmonary edema in about 2%. Ventricular arrhythmias or conduction disturbances each occurred in fewer than 0.5% of patients.

Laboratory Tests: Rare, mild to moderate, transient elevations of enzymes such as alkaline phosphatase, CPK, LDH, SGOT, and SGPT have been noted, and a single incident of significantly elevated transaminases and alkaline phosphatase was seen in a patient with a history of gall bladder disease after about eleven months of nifedipine therapy. The relationship to PROCARDIA therapy is uncertain. These laboratory abnormalities have rarely been associated with clinical symptoms. Cholestasis, possibly due to PROCARDIA therapy, has been reported twice in the extensive world literature.

HOW SUPPLIED: Each orange, soft gelatin PROCARDIA CAPSULE contains 10 mg of nifedipine. PROCARDIA CAPSULES are supplied in bottles of 100 (NDC 0069-2600-66), 300 (NDC 0069-2600-72), and unit dose (10x10) (NDC 0069-2600-41). The capsules should be protected from light and moisture and stored at controlled room temperature 59° to 77°F (15° to 25°C) in the manufacturer's original container.

More detailed professional information available on request.

© 1982, Pfizer Inc.



LABORATORIES DIVISION
PFIZER INC.

THEO-DUR®

(anhydrous theophylline)
Sustained Action Tablets

**Protection when it's
needed most.**

Description: THEO-DUR Sustained Action Tablets contain anhydrous theophylline, with no color additives.

Pharmacologic Actions: The pharmacologic actions of theophylline are as a bronchodilator, pulmonary vasodilator and smooth muscle relaxant since the drug directly relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels. Theophylline also possesses other actions typical of the xanthine derivatives: coronary vasodilator, diuretic, cardiac stimulant, cerebral stimulant and skeletal muscle stimulant. The actions of theophylline may be mediated through inhibition of phosphodiesterase and a resultant increase in intracellular cyclic AMP which could mediate smooth muscle relaxation.

Indications and Usage: Symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.

Contraindications: THEO-DUR is contraindicated in individuals who have shown hypersensitivity to any of its components or xanthine derivatives.

Warnings: Excessive theophylline doses may be associated with toxicity; serum theophylline levels should be monitored to assure maximum benefit with minimum risk. Incidence of toxicity increases at serum levels greater than 20 mcg/ml. High blood levels of theophylline resulting from conventional doses are correlated with clinical manifestation of toxicity in patients with lowered body plasma clearances, patients with liver dysfunction or chronic obstructive lung disease, and patients who are older than 55 years of age, particularly males. There are often no early signs of less serious theophylline toxicity such as nausea and restlessness, which may appear in up to 50% of patients prior to onset of convulsions. Ventricular arrhythmias or seizures may be the first signs of toxicity. Many patients who have higher theophylline serum levels exhibit a tachycardia. Theophylline products may worsen pre-existing arrhythmias.

Usage in Pregnancy: Safe use in pregnancy has not been established relative to possible adverse effects on fetal development, but neither have adverse effects on fetal development been established. This is, unfortunately, true for most anti-asthmatic medications. Therefore, use of theophylline in pregnant women should be balanced against the risk of uncontrolled asthma.

Precautions: THEO-DUR TABLETS SHOULD NOT BE CHEWED OR CRUSHED. Theophyllines should not be administered concurrently with other xanthine medications. It should be used with caution in patients with severe cardiac disease, severe hypoxemia, hypertension, hyperthyroidism, acute myocardial injury, cor pulmonale, congestive heart failure, liver disease, and in the elderly, particularly males, and in neonates. Great caution should be used in giving theophylline to patients in congestive heart failure since these patients show markedly prolonged theophylline blood level curves. Use theophylline cautiously in patients with history of peptic ulcer. Theophylline may occasionally act as a local irritant to G.I. tract, although gastrointestinal symptoms are more commonly central and associated with high serum concentrations above 20 mcg/ml.

Adverse Reactions: The most consistent adverse reactions are usually due to overdose and are:

Gastrointestinal: Nausea, vomiting, epigastric pain, hematemesis, diarrhea.

Central Nervous System: Headaches, irritability, restlessness, insomnia, reflex hyperexcitability, muscle twitching, clonic and tonic generalized convulsions.

Cardiovascular: Palpitation, tachycardia, extrasystoles, flushing, hypotension, circulatory failure, life threatening ventricular arrhythmias.

Respiratory: Tachypnea.

Renal: Albuminuria, increased excretion of renal tubular cells and red blood cells, potentiation of diuresis.

Others: Hyperglycemia and inappropriate ADH syndrome.

How Supplied: THEO-DUR 100 mg, 200 mg and 300 mg Sustained Action Tablets are available in bottles of 100, 500, 1000, and 5000, and in unit dose packages of 100.

Caution: FEDERAL LAW PROHIBITS DISPENSING WITHOUT A PRESCRIPTION.

For full prescribing information, see package insert. 0881

References

1. Hetzel MR, Clark TJH: *Thorax* 35:732, 1980.
2. Riegelman S: The pharmacokinetics of successful theophyllinization, in *Update: Theophylline Management*. New York, KPR Inform/Media Corp, 1980, p 8.
3. Jenne JW: Controversies in theophylline therapy, in *Update: Theophylline Management*. New York, KPR Inform/Media Corp, 1980, p 16.
4. Hetzel MR, Clark TJH, Branthwaite MA: *Br Med J* 1:808, 1977.
5. Jenne JW: *Lung* 159:295, 1981.
6. Bell T, Bigley J: *Pediatrics* 62:352, 1978.
7. Levy G, Koysooko R: *J Pediatr* 86:789, 1975.
8. Mitenko PA, Ogilvie RI: *N Engl J Med* 289:600, 1973.
9. Jenne JW, Wyse MS, Rood FS, et al: *Clin Pharmacol Ther* 13:349, 1972.
10. Ekwo E, Weinberger MM: *J Allergy Clin Immunol* 61:240, 1978.
11. Data on file, Key Pharmaceuticals, Inc.



KEY PHARMACEUTICALS, INC.
Miami, Florida 33169-1307
**World leader in
drug delivery systems.**

TD-1194

(Continued from Page 632)

December 10—The Danielle Aron-Rosa YAG Laser Symposium. Centinela Hospital Medical Center, Inglewood. Saturday. 6 hrs. \$175. Contact: Marjorie Cohan, RN, Med. Ed. Dept., Centinela Hospital, 555 E. Hardy St., Inglewood 90307. (213) 673-4660, ext. 8213.

December 12-16—Basic Microsurgery Training Workshop. UCSD. Monday-Friday. 34 hrs. \$1,200.

December 16—All Day Clinical Conference—Ophthalmology. USC and Estelle Doheny Eye Foundation at Los Angeles. Friday. Contact: USC/EDEF, 1355 San Pablo St., Los Angeles 90033. (213) 224-7752.

January 6—State of the Art Symposium—Otosclerosis. Pacific Medical Center/Northern California Transplant Bank at Marriott Biltmore, Santa Barbara. Friday. Contact: Mansfield F. W. Smith, MD, P.O. Box 7999, San Francisco 94120.

January 13-14—11th Annual Santa Clara County Surgical Seminar. Santa Clara County Surgical Seminar Association at Hyatt, San Jose. Friday-Saturday. 16 hrs. \$175. Contact: Surgical Seminar, c/o K. Watanabe, MD, 150 N. Jackson Ave., No. 209, San Jose 95116.

January 13-14—Photocoagulation Workshop. Jules Stein Eye Institute, Los Angeles. Friday-Saturday. 16 hrs. \$450. Contact: Lu Hendricks, Academic Programs Admin., JSEI, UCLA School of Medicine, Center for the Health Sciences, Los Angeles 90024.

January 16-20—Basic Microsurgery Training Workshop. UCSD. Monday-Friday. 34 hrs. \$1,200.

January 20-21—6th Annual Postgraduate Course in Surgery. UCD at Capital Plaza Holiday Inn, Sacramento. Friday-Saturday.

January 22-25—53rd Mid-Winter Conference in Ophthalmology. Research Study Club at Hilton Hotel, Los Angeles. Sunday-Wednesday. Contact: Research Study Club, P.O. Box 49412, Los Angeles 90049.

January 23-26—Postgraduate Assembly in Surgery. UCSD at Sheraton Harbor Island Hotel, San Diego. Monday-Thursday. 28 hrs.

January 28—Update on Strabismus and Pediatric Ophthalmology. Jules Stein Eye Institute, Los Angeles. Saturday. \$85. Contact: Lu Hendricks, Academic Program Admin., JSEI, UCLA School of Medicine, Center for the Health Sciences, Los Angeles 90024.

January 28-February 4—Temporal Bone Surgical Dissection—1984. House Ear Institute, Los Angeles. One week. 62 hrs. \$850. Contact: Antonio de la Cruz, MD, Director of Education, HEI, 256 S. Lake St., Los Angeles 90057. (213) 483-4431.

February 4—Ophthalmology Residents and Fellows Day. Jules Stein Eye Institute, Los Angeles. Saturday. 6 hrs. Contact: Lu Hendricks, Academic Program Admin., JSEI, UCLA School of Medicine, Center for the Health Sciences, Los Angeles 90024.

February 13-17—Trauma Management 1984. UCSD. Monday-Friday.

February 23-26—Federation of Western Societies of Neurological Science—Annual Meeting at Silverado Country Club, Napa. Wednesday-Saturday. Contact: Program Chairman, Franklin C. Wagner, Jr, MD, Dept. of Neurological Surgery, University of California, Davis Medical Center, 4301 X St., Sacramento 95817.

February 27-March 2—Basic Microsurgery Training Workshop. UCSD. Monday-Friday. 34 hrs. \$1,200.

March 1-2—Annual Postgraduate Seminar—Retina and Choroid: Vascular, Inflammatory and Degenerative Disease. Jules Stein Eye Institute at Century Plaza Hotel, Los Angeles. Thursday-Friday. 16 hrs. \$375. Contact: Lu Hendricks, Academic Program Admin., JSEI, UCLA School of Med., Center for Health Sciences, Los Angeles 90024.

March 5-9—Surgical Forum. Society of Graduate Surgeons of the Los Angeles County and USC Medical Center at Ambassador Hotel, Los Angeles. Monday-Friday. 31 hrs. Contact: Dir. of Med. Ed., Soc. of Graduate Surgeons, 5820 Wilshire Blvd., #500, Los Angeles 90036. (213) 937-5514.

- March 9-11—**Pathophysiology and Techniques of Cardiopulmonary Bypass IV.** Cardiothoracic Research and Education Foundation and UCSD at Sheraton Harbor Island East, San Diego. Friday-Sunday. 16 hrs. \$250. Contact: CREF, P.O. Box 33185, San Diego 92103. (619) 272-3126.
- March 10-11—**California Association of Neurological Surgeons Meeting** at Pasadena. Saturday-Sunday.
- March 19-23—**Basic Microsurgery Training Workshop.** UCSD. Monday-Friday. 35 hrs. \$1,200.
- March 23-25—**Gynecologic Surgery with Emphasis on Gynecologic Urology.** See Obstetrics and Gynecology, March 23-25.
- March 24-25—**Pediatric Orthopedics.** See Pediatrics, March 24-25.
- March 24-28—**21st Annual UCLA Seminar on Controversial Areas in Surgery.** UCLA at Palm Springs. Saturday-Wednesday. 14 hrs. \$410.
- March 26-30—**Advanced Microsurgery Training Workshop.** UCSD. Monday-Friday. 35 hrs. \$1,200.
- March 31—**Modern Ophthalmologic Procedures: ERG, VER, Ultrasonography, Tonography, Eye Movement Analysis, and Octopus Quantitative Perimetry.** Jules Stein Eye Institute, Los Angeles. Saturday. 8 hrs. \$85. Contact: Lu Hendricks, Academic Program Admin., JSEI, UCLA School of Medicine, Center for the Health Sciences, Los Angeles 90024.
- March 28-April 1—**12th Annual Symposium on Vascular Surgery.** UCLA at Palm Springs. Wednesday-Sunday. 16.5 hrs. \$445.

OF INTEREST TO ALL PHYSICIANS

- November 20-23—**4th Annual Sports Medicine Now Program.** The American College of Sports Medicine and the University of Hawaii at Kapalua Bay Hotel, Maui, Hawaii. Sunday-Wednesday. 25 hrs. \$300. Contact: Stuart Zeman, MD, Sports Medicine Now, 2025 Morse Ave., Sacramento 95825. (916) 486-5834.
- December 2—**AIDS and Genital Herpes.** Waikiki Health Center at Ala Moana Americana Hotel, Hawaii. Friday. 8 hrs. Contact: Yvonne Brewer, MPH, 1188 Bishop St., Ste. 3411, Honolulu, HI 96813. (808) 524-3540.
- December 2-4—**Emerging Frontiers in Medicine.** The Cypress Foundation, UCSF, and Monterey County Medical Society at Hyatt Del Monte, Monterey. Friday-Sunday. 14 hrs. Contact: The Cypress Foundation, P.O. Box 80308, Salinas 93912. (408) 455-1833.
- December 7-10—**International Symposium on Basic Mechanism of Epilepsies.** UCLA at Kona Kai Hotel, San Diego. Wednesday-Saturday. 26 hrs. \$125.
- December 9-10—**Genetics, Birth Defects and the High Risk Patient.** UCD at Capitol Plaza, Sacramento. Friday-Saturday.
- December 13-16—**Sexually Transmitted Diseases.** Honolulu Medical Group Research and Education Foundation at Prince Kuhio Hotel, Honolulu. Tuesday-Friday. 16 hrs. Contact: Yvonne Brewer, MPH, Ed. Dir., HMGREF, 550 Beretania St., Honolulu, HI 96813. (808) 537-2211, ext. 751.
- December 14—**Complications of Dialysis: Their Diagnosis and Management.** LLU. Wednesday. 4 hrs. \$50.
- December 31—**3rd Annual Potpourri of Medicine Seminar.** Huntington Memorial Hospital, Pasadena. Saturday. 6 hrs. \$110. Contact: Medical Staff Coordinator, HMH, 100 Congress St., Pasadena 91105. (213) 550-5165.
- January 12-13—**New Developments in Asbestos-Related Disease.** UCI at South Coast Plaza Hotel, Costa Mesa. Thursday-Friday. 14 hrs. \$200.
- January 19-21—**Physician and the Hospital.** USC at Palm Springs Hilton, Palm Springs. Thursday-Saturday. \$250.
- January 20-22—**Practical Dermatology and Dermatologic Office Procedures for the Primary Care Physician.** UCSD at Vacation Village Hotel, San Diego. Friday-Sunday. 20 hrs. \$295.
- January 23-27—**Primary Care.** UCSF at Golden Gateway Holiday Inn, San Francisco. Monday-Friday.
- January 27-29—**American College of Physicians 1984 Regional Meeting** at Vacation Village, San Diego. Friday-

- Sunday. Contact: Thomas J. Lehar, FACP, 2001 4th Ave., San Diego 92101.
- February 1-3—**Neurology for Non-Neurologists.** UCSD at San Diego Hilton Hotel, San Diego. Wednesday-Friday. 21 hrs. \$325.
- February 3-4—**Human Sexuality for the Health Professional.** Mental Research Institute, Palo Alto. Friday-Saturday. 10 hrs. \$100. Contact: Training Programs, MRI, 555 Middlefield Rd., Palo Alto 94301. (415) 321-3055.
- February 10-15—**California Medical Association Annual Session** at Disneyland Hotel, Anaheim. Friday-Wednesday. Contact: Carolyn Grandy, California Medical Association, 44 Gough St., San Francisco 94103. (415) 863-5522.
- February 12-17—**Sports Medicine.** UCD at Hyatt, Lake Tahoe. Sunday-Friday.
- February 13-17—**American College of Physicians MKSAP VI Course** at San Francisco. Monday-Friday. Contact: Registrar, ACP, 4200 Pine St., Philadelphia, PA 19104.
- February 13-18—**UCI Family Practice Refresher Course.** UCI at Marriott Hotel, Newport Beach. Monday-Saturday.
- February 19-22—**4th Annual Conference on Alcoholism and Chemical Dependency Problem Sharing/Solving in Chemical Dependency.** Annenberg Center for Health Sciences of the Eisenhower Medical Center, Rancho Mirage. Sunday-Wednesday. Contact: Annenberg Center for Health Sciences—A, 39000 Bob Hope Dr., Rancho Mirage 92270. (800) 621-7322.
- February 23-24—**American College of Physicians 1984 Regional Meeting** at Ala Moana Hotel, Honolulu, HI. Thursday-Friday. Contact: Robert A. Nordyke, FACP, 2013 Kakaia Dr., Honolulu, HI 96822.
- March 2-3—**American College of Physicians 1984 Regional Meeting** at Holiday Inn, Napa. Friday-Saturday. Contact: Jerry P. Lewis, FACP, 618 Francisco Place, Davis 95616.
- March 7-9—**34th Annual Course for Physicians in Family Practice.** Mt. Zion Hospital and Medical Center, San Francisco. Wednesday-Friday. Contact: Office of Continuing Ed., Mt. Zion Hospital, P.O. Box 7921, San Francisco 94120. (415) 567-6600, ext. 2404.
- March 12-16—**University of Hawaii Sports Medicine Course** at Princess Kaiulani Hotel, Waikiki, Honolulu, HI. Monday-Friday. \$280. Contact: Ms. Joy Lewis, Box CEW-CCECS, 2530 Dole St., Honolulu, HI 96822. (808) 948-8244.
- March 14-17—**Contemporary Obstetrics: A Guide to the Physician in Practice.** See Obstetrics and Gynecology, March 14-17.
- March 16-18—**Office Emergencies in Primary Care.** Sharp Memorial Hospital at Hotel del Coronado, Coronado. Friday-Sunday. 20 hrs. \$250. Contact: Jackie Shiller, Continuing Medical Education Associates, P.O. Box 84296, San Diego 92138. (619) 223-2997.
- March 22-24—**Postgraduate Institute.** California Medical Association at Yosemite. Thursday-Saturday.
- March 24—**Alcoholism: 1984.** UCD at Red Lion Motor Inn, Sacramento. Saturday.
- March 25-28—**Nutrition Conference.** UCSF at Yosemite. Sunday-Wednesday.
- March 26-30—**Family Medicine Board Review Course.** UCSD at Palm Springs. Monday-Friday.
- March 29-30—**1984 Updates: Medical and Behavioral Treatment.** Scripps Clinic and Research Foundation, La Jolla. Thursday-Friday. Contact: Dianne Tisue, Conference Coordinator, Scripps Clinic and Research Fndn, 10666 N. Torrey Rd., La Jolla 92037. (714) 455-9100.

IDAHO

- January 28-February 4—**Far Western Medical Association—Winter Scientific Meeting—What's New in Medicine?** Sun Valley. One week. Contact: FWMA, P.O. Box 3817, Van Nuys, CA 91407.

(Continued on Page 640)

MONTANA

March 22-24—**Big Sky Lung Summit.** American Lung Assn. of Montana at Big Sky of Montana "Ski the Sky." Thursday-Saturday. Contact: ALA of Montana, 825 Helena Ave., Helena, MT 59601. (406) 442-6556.

NEW MEXICO

All courses listed below have been certified by CME accredited institutions as meeting the criteria for Category 1 of the Physician's Recognition Award of the American Medical Association. The Continuing Medical Education Committee of the New Mexico Medical Society has certified all courses listed below as meeting the criteria for Category IV under the New Mexico Board of Medical Examiners Continuing Medical Education regulations.

Information, requests for accreditation and items to be listed should be sent to the chairman of the CME Committee, New Mexico Medical Society, 303 San Mateo NE, Suite 204, Albuquerque, NM 87108 at least two months in advance. For information on CME accreditation or on the CME requirements of the New Mexico Board of Medical Examiners, please write to the above address or call (505) 266-7868.

NOTE: Course information in the following listing is subject to change on occasion. Check with the sponsoring institution for current details.

November 18—**New Concepts in Cancer.** Los Alamos. Friday. Los Alamos Meson Physics Facility Auditorium. 6 hrs. AMA Cat. I, NM Cat. IV. Contact: Peter J. Lindberg, MD, P.O. Box 995, Los Alamos 87544. (505) 662-3450.

December 2-3—**Trauma Update '83.** Albuquerque. Friday-Saturday. Convention Center/Regent Hotel. 11 hrs. NM Cat. IV. Contact: Marjorie Lalicker, UNM Cont. Med. Ed., No. Campus, Bldg. M-2, Albuquerque 87131. (505) 277-3942.

February 6-10—**Alta Medical Conference: Diabetes 1984.** Monday-Friday. Alta, Utah. 10 hrs. AMA Cat. I, NM Cat. IV. Contact: Neil I. Kaminsky, MD, 717 Encino Pl., NE, Albuquerque 87102. (505) 842-6762.

March 18-21—**Rural Health Care: Bringing It Home.** Albuquerque. Sunday-Wednesday. Convention Center. 19 hrs. AMA Cat. I, NM Cat. IV. Contact: Judy Harris, RN, New Mexico Health Resources, Inc., P.O. Box 8735, Albuquerque 87198.

OREGON

The following list of continuing medical education offerings in the state of Oregon is compiled by the Oregon Medical Association's Council on Medical Education. If you wish to submit information regarding future postgraduate courses, please submit the information to Veronica Story, Secretary to the Council on Medical Education, 5210 SW Corbett Ave., Portland, OR 97201, or phone (503) 226-1555.

MEDICAL GRAND ROUNDS

Douglas Community Hospital, 738 West Harvard Avenue, Roseburg 97470:

Every Monday 12:30 p.m. Contact: Robert A. Driver, MD, Douglas Community Hospital, 738 West Harvard Avenue, Roseburg, OR 97470. (503) 673-6641.

Emanuel Hospital, 2801 N. Gantenbein Street, Portland 97227:

Every Friday, 8:00 a.m. to 9:00 a.m. **Medical Grand Rounds.** Contact: Philipa McClure, Emanuel Hospital, 2801 N. Gantenbein St., Portland, OR 97227. (505) 280-3200.

Good Samaritan Hospital and Medical Center, 1015 NW 22nd Avenue, Portland 97210:

Every Wednesday, 8:00 a.m. to 9:00 a.m. **Medicine Grand Rounds.** Contact: Chris Cobb, Good Samaritan Hospital and Medical Center, 1015 NW 22nd Avenue, Portland, OR 97201. (503) 229-7111.

Providence Medical Center, 4805 NE Glisan, Portland 97213:

Every Wednesday, 8:00 a.m. **Medical Grand Rounds.** Contact: Richard Wernick, MD, Providence Medical Center, 4805 NE Glisan, Portland, OR 97213. (503) 230-6085.

Sacred Heart General Hospital, 1200 Alder Street, Eugene, OR 97440:

Every Tuesday, 8:00-9:00 a.m. **Medical Grand Rounds.** Hospital Auditorium. Contact: Medical Education Committee, P.O. Box 10905, Eugene, OR 97440.

Salem Hospital, 665 Winter Street SE, Salem 97301:

First and third Thursday of each month 7:15 a.m. to 8:15 a.m. **Medical Live Audit Conference.** Memorial Auditorium. Contact: Diane Eyerly, Salem Hospital, 665 Winter St. SE, Salem, OR 97301. (503) 370-5339.

Every Friday, 7:30 a.m. to 8:30 a.m. **Friday Grand Rounds.** Memorial Auditorium. Contact: Diane Eyerly, Salem Hospital, 665 Winter St. SE, Salem, OR 97301. (503) 370-5339.

St. Vincent Hospital & Medical Center, 9205 SW Barnes Rd., Portland 97225:

First, third, fourth and fifth Wednesday of each month, 8:00 a.m. to 9:00 a.m. **Medical Grand Rounds.** Souther Auditorium. Contact: Bonnie Conger, Secretary to Dr. Kenneth Melvin, St. Vincent Hospital & Medical Center, 9205 SW Barnes Rd., Portland 97225. (503) 297-4411, Ext. 2230.

Oregon Health Sciences University, Department of Psychiatry, Portland 97201:

Every Wednesday, 4:00 p.m. to 5:00 p.m.—**Department of Psychiatry Grand Round Presentations.** Room 8B-60, University Hospital South. Oregon Health Sciences University. Contact: Dept. of Psychiatry, Oregon Health Sciences University, Portland, OR 97201. (503) 225-8144.

Oregon Health Sciences University, Department of Medicine, Portland 97201:

Every Tuesday, 8:00 a.m. to 9:00 a.m.—**Department of Medicine Grand Rounds.** U.H.S.-8B-60, Oregon Health Sciences University. Contact: Dept. of Medicine, Oregon Health Sciences University, Portland, OR 97201. (503) 225-8607.

FAMILY PRACTICE GRAND ROUNDS

Every Wednesday, 11:00 a.m. to 12:00 Noon. **Family Practice Grand Rounds.** Family Practice Center, Oregon Health Sciences University, Portland. Contact: William A. Fisher, MD, Oregon Health Sciences University, Department of Family Practice, Portland, OR 97201. (503) 225-7590.

* * * *

EMERGENCY MEDICINE

February 2-4—**Evaluation and Management of Medical Emergencies.** Bend. Thursday-Saturday. Inn of the Seventh Mountain-Mt. Bachelor. Contact: Veronica Story, Oregon Chap., Am. College of Emergency Physicians. (503) 226-1555.

FAMILY PRACTICE

February 13-17—**15th Annual Family Practice Review.** Portland. Monday-Friday. Marriott Hotel. Contact: OHSU-CME.

May 18-19—**Orthopedics for the Primary Care Physician.** Portland. Friday-Saturday. Red Lion Motor Inn at Jantzen Beach. Contact: OHSU-CME.

(Continued on Page 644)

CONTACT INFORMATION

OHSU-CME—Contact: Division of Continuing Medical Education, Oregon Health Sciences University, Portland, OR 97201. (503) 225-8700.

**XANAX® Tablets &
(alprazolam)**

CONTRAINDICATIONS

Patients with sensitivity to this drug or other benzodiazepines and in acute narrow angle glaucoma.

WARNINGS

Not of value in psychotic patients. Caution patients against hazardous occupations requiring complete mental alertness and about the simultaneous ingestion of alcohol and other CNS depressant drugs.

Benzodiazepines can cause fetal harm in pregnant women. Warn patients of the potential hazard to the fetus. Avoid during the first trimester.

PRECAUTIONS

General: If XANAX is combined with other psychotropics or anti-convulsant drugs, consider drug potentiation. Exercise the usual precautions regarding size of the prescription for depressed or suicidal patients. In elderly and debilitated patients, use the lowest possible dosage. Observe the usual precautions in treating patients with impaired renal or hepatic function.

Information for Patients: Alert patients about: (a) consumption of alcohol and drugs, (b) possible fetal abnormalities, (c) operating machinery or driving, (d) not increasing dose of the drug due to risk of dependence, (e) not stopping the drug abruptly. **Laboratory Tests:** Not ordinarily required in otherwise healthy patients. **Drug Interactions:** Additive CNS depressant effects with other psychotropics, anticonvulsants, antihistamines, ethanol and other CNS depressants. Pharmacokinetic interactions with benzodiazepines have been reported. **Drug/Laboratory Test Interactions:** No consistent pattern for a specific drug or specific test. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** No carcinogenic potential or impairment of fertility in rats. **Pregnancy:** See Warnings. **Nonteratogenic Effects:** The child born of a mother on benzodiazepines may be at some risk for withdrawal symptoms and neonatal flaccidity. **Labor and Delivery:** No established use. **Nursing Mothers:** Benzodiazepines are excreted in human milk. Women on XANAX should not nurse. **Pediatric Use:** Safety and effectiveness in children below the age of 18 have not been established.

ADVERSE REACTIONS

Side effects are generally observed at the beginning of therapy and usually disappear with continued medication. In the usual patient, the most frequent side effects are likely to be an extension of the pharmacological activity of XANAX, e.g., drowsiness or lightheadedness.

Central Nervous System: Drowsiness, lightheadedness, depression, headache, confusion, insomnia, nervousness, syncope, dizziness, akathisia, and tiredness/sleepiness.

Gastrointestinal: Dry mouth, constipation, diarrhea, nausea/vomiting, and increased salivation.

Cardiovascular: Tachycardia/palpitations, and hypotension.

Sensory: Blurred vision.

Musculoskeletal: Rigidity and tremor.

Cutaneous: Dermatitis/allergy.

Other Side Effects: Nasal congestion, weight gain, and weight loss.

In addition, the following adverse events have been reported with the use of anxiolytic benzodiazepines: dystonia, irritability, concentration difficulties, anorexia, loss of coordination, fatigue, sedation, slurred speech, jaundice, musculoskeletal weakness, pruritus, diplopia, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retention.

Paradoxical reactions such as stimulation, agitation, increased muscle spasticity, sleep disturbances, and hallucinations may occur. Should these occur, discontinue the drug.

During prolonged treatment, periodic blood counts, urinalysis, and blood chemistry analyses are advisable. Minor EEG changes, of unknown significance, have been observed.

DRUG ABUSE AND DEPENDENCE

Physical and Psychological Dependence: Withdrawal symptoms have occurred following abrupt discontinuance of benzodiazepines. After prolonged therapy, dosage should be tapered. **Controlled Substance Class:** XANAX is a controlled substance and has been assigned to schedule IV.

DOSAGE AND ADMINISTRATION

The usual starting dose is 0.25 to 0.5 mg, t.i.d. Maximum total daily dose is 4 mg. In the elderly or debilitated, the usual starting dose is 0.25 mg, two or three times daily.

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION.

BS-1

Upjohn

THE UPJOHN COMPANY
Kalamazoo, Michigan 49001 USA

(Continued from Page 640)

SURGERY

December 9-10—Soft Tissue Surgery Techniques. Portland. Friday-Saturday. OHSU campus. Contact: OHSU-CME.

March 2-3—Difficult Problems in Surgery. Portland. Friday-Saturday. Red Lion-Lloyd Center. Contact: OHSU-CME.

INTEREST TO ALL PHYSICIANS

November 17-18—Symposium on Critical Care Medicine. Portland. Thursday-Friday. Red Lion Motor Inn at Jantzen Beach. Contact: OHSU-CME.

December 2-3—Topics in Internal Medicine. Portland. Friday-Saturday. Marriott Hotel. Contact: OHSU-CME.

March 8-9—Occupational Medicine. Portland. Thursday-Friday. Red Lion at Jantzen Beach. Contact: OHSU-CME.

UTAH

This listing of continuing medical education courses in Utah is compiled and edited by the Academy for Continuing Medical Education, a foundation of the Utah State Medical Association. All courses listed have been certified by CME accredited institutions as meeting the criteria for Category 1 of the Physician's Recognition Award of the American Medical Association. They also must meet the definition of Utah Approved CME Credit for the purpose of medical license reregistration in Utah. Accredited institutions wishing to list AMA Category 1/Utah Approved CME courses here should send information at least two months in advance to the Academy for Continuing Medical Education, 540 East Fifth South, Salt Lake City, Utah 84102; or phone (801) 355-5290. For information on CME accreditation or on the CME requirements of the Utah Physicians' Licensing Board, please write the Academy at the above address.

NOTE: Course information in the following listing is subject to change on occasion. Check with the sponsoring institution or the Academy for current details.

PEDIATRIC GRAND ROUNDS

Primary Children's Medical Center, 320 12th Ave., Salt Lake City 84103:

First and Third Thursdays—8:00 a.m. Contact: Cathy Van Komen, PCMC, 320 12th Ave., Salt Lake City, UT 84103. (801) 363-1221.

MONTHLY PSYCHOTHERAPY CLINICAL SEMINAR

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

First Monday—7-9 a.m. Contact: Jack Tedrow, MD, (801) 363-2024.

FAMILY PRACTICE GRAND ROUNDS

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Every Wednesday—8:00-9:00 a.m. Contact: Thomas Schwenk, MD, (801) 581-8633.

CITYWIDE OB/GYN CLINICAL CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Second Saturday—8-9 a.m. Contact: Howard Berk, MD, (801) 364-4438.

OB/GYN PATHOLOGY CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

(Continued on Page 759)

Books Received

Books received by THE WESTERN JOURNAL OF MEDICINE are acknowledged in this column. Selections will be made for more extensive review in the interest of readers as space permits.

PLATELETS: PATHOPHYSIOLOGY AND ANTIPLATELET DRUG THERAPY—Harvey J. Weiss, MD, Professor of Medicine, College of Physicians & Surgeons of Columbia University; Director, Division of Hematology-Oncology, St. Luke's-Roosevelt Hospital Center, New York. Alan R. Liss, Inc., 150 Fifth Ave., New York, NY 10011, 1982. 165 pages, \$22.00.

THE POLITICS OF REPRODUCTIVE RITUAL—Karen Erickson Paige & Jeffery M. Paige. University of California Press, 2223 Fulton St., Berkeley, CA 94720, 1983. 380 pages, \$8.95 (softbound).

PRACTICAL MANAGEMENT OF EMOTIONAL PROBLEMS IN MEDICINE—Revised Edition—Hugh James Lurie, MD, Clinical Professor of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle. Raven Press, 1140 Avenue of the Americas, New York, NY 10036, 1982. 243 pages, \$24.00.

PRACTICAL PULMONARY DISEASE—Edited by Irwin Ziment, MD, Professor, Department of Medicine, University of California, Los Angeles, School of Medicine, and Chief, Department of Medicine, Olive View Medical Center, Van Nuys, California. John Wiley & Sons, Inc., One Wiley Drive, Somerset, NJ 08873, 1983. 218 pages, \$14.95.

A PRIMER OF ORTHOPAEDIC BIOMECHANICS—George Van B. Cochran, MD, MScD, Director, Orthopaedic Engineering and Research Center, Helen Hayes Hospital, West Haverstraw, NY; Professor of Clinical Orthopaedic Surgery, College of Physicians and Surgeons, Columbia University, New York. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036, 1982. 413 pages, \$48.00.

PRINCIPLES OF PEDIATRIC PHARMACOLOGY—Volume Six of MONOGRAPHS IN CLINICAL PHARMACOLOGY—Lars O. Boréus, MD, Professor and Chairman, Department of Clinical Pharmacology, Karolinska Hospital, Stockholm. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036, 1982. 212 pages, \$32.00.

PRINCIPLES AND PRACTICE OF BLOOD-GAS ANALYSIS—A. P. Adams, PhD (LOND), MB, BS, MRCS, LRCP, FFA, RCS, DA, Professor of Anaesthetics in the University of London, Guy's Hospital Medical School, London, and C. E. W. Hahn, MA, D Phil (OXON), MSc, BSc, University Lecturer in Anaesthetics, Nuffield Department of Anaesthetics, University of Oxford. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036. 95 pages, \$19.50 (softbound).

PULMONARY EMERGENCIES—Edited by Steven A. Sahn, MD, Associate Professor of Medicine, University of Colorado Health Sciences Center; Attending Physician, Medical Intensive Care Unit, University Hospital; Director, Pleural Space Laboratory, Webb-Waring Lung Institute, Denver. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036, 1982. 415 pages, \$42.00.

RADIOLOGY OF SKELETAL TRAUMA—Volumes 1 & 2—Lee F. Rogers, MD, Professor and Chairman, Department of Radiology, Northwestern University Medical School, Chicago. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036, 1982. 920 pages, \$175.00.


REAL-TIME ULTRASONOGRAPHY—Volume 10 of CLINICS IN DIAGNOSTIC ULTRASOUND—Edited by Fred Winsberg, MD, Professor, Department of Diagnostic Radiology, McGill University Faculty of Medicine, Diagnostic Radiologist-in-Chief, Montreal General Hospital; and Peter L. Cooperberg, MD, Associate Professor, Department of Radiology, University of British Columbia Faculty of Medicine, Chief, Section of Ultrasound, Department of Diagnostic Radiology, Vancouver General Hospital. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036, 1982. 321 pages, \$27.00.

RECENT DEVELOPMENTS IN CARDIOVASCULAR DRUGS—Edited by John Coltart, MD, MRCP, FACC, Consultant Physician in Cardiology, St. Thomas' Hospital, London, and David E. Jewitt, BSc, MB, BS, FRCP, Director of Cardiac Department and Consultant Cardiologist, King's College Hospital, London. Churchill Livingstone, Inc., 1560 Broadway, New York, NY 10036, 1982. 348 pages, \$59.00.

SEGMENTAL ANATOMY—Application to Clinical Medicine—Marvin Wagner, MD, MS (Anatomy), Clinical Professor of Surgery and Clinical Professor of Anatomy, Medical College of Wisconsin, Milwaukee, and Thomas L. Lawson, MD, Professor of Radiology and Chief, Section of Computed Body Tomography and Ultrasonography, Medical College of Wisconsin, Milwaukee. 650 pages, \$95.00, 1982, Macmillan Publishing Co., Inc., 866 Third Ave., New York, NY 10022.

THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE—Paul Starr, PhD, Associate Professor of Sociology, Harvard University, Cambridge. 514 pages, \$24.95, 1982, Basic Books, Inc., Publishers, 10 East 53rd St., New York, NY 10022.

PHYSICIANS



We are announcing opportunities for you to serve your country as an Air Force Reserve physician/officer. You can make new professional associations, obtain CME credit and help support the Air Force mission. For those who qualify, retirement credit can be obtained as well as low cost life insurance. One weekend a month plus two weeks a year or less can bring you pride and satisfaction in serving your country.

Call Collect:
(916) 643-2432
Or Write:
Health Professions Recruiting
4 AF/RSB
McClellan AFB, CA 95652

AIR FORCE RESERVE 4-308-1055

A GREAT WAY TO SERVE

Snowbird Conferences

Sponsored by
University of Utah School of Medicine

March 5-9, 1984

ADVANCES IN INTERNAL MEDICINE

\$275 fee, CME Credit Available

March 12-16, 1984

MEDICAL AND SURGICAL ADVANCES IN GASTROENTEROLOGY

\$275 fee, CME Credit Available

Park City Conference

March 26-30, 1984

NUTRITION IN CONTEMPORARY MEDICINE

\$225 fee, CME Credit Available

Information/Registration:

Jennifer Fossum
Division of Gastroenterology
University Medical Center
Salt Lake City, UT 84132
(801) 581-3581

CLINICAL STUDIES

Wanted Hospital and Clinic Administrators to bring their institutions into the advancing world of clinical studies. Do you have:

- Experienced clinicians with adequate training in a particular discipline,
- Modern facilities and an adequate number of eligible patients
- Access to certified clinical laboratory facilities?

Clinical Investigational Services will bring your institution and the new drug sponsors together and provide the necessary expertises to move the clinical studies forward.

ADEQUATE OPPORTUNITIES AND REWARDS FOR ALL.

Please send the curriculum vitae of your clinical specialists and description of your institution to:

CLINICAL INVESTIGATIONAL SERVICES
P.O. Box 63, Summit, NJ 07901

(Continued from Page 752)

PRACTICES AVAILABLE

TWO FP AND EMERGENCY CLINICS in High Sierra mountains ski resort. Established 14 years. Gross 600 to 700 K per year. PA, x-ray, \$390,000. Details (619) 934-9753.

GENERAL FAMILY PRACTICE for sale in fast growing area of South Sacramento. For information write: Anderson, 1442 El Nido Way, Sacramento, CA 95825.

OB-GYN PRACTICE FOR SALE, Flagstaff, Arizona. Available immediately. Physician leaving for fellowship, 300+ deliveries yearly. Terms: Call (602) 774-3411 or write Jerry G. Martin, MD, 1300 A Rim Drive, Flagstaff, AZ 86001.

CALIFORNIA—HIGH INCOME practices available Internal, Family, OBG, Pediatric, invasive/non-invasive Cardiology, others. Mary Bradshaw, 21 Altamont Dr., Orinda, CA 94563; (415) 376-0762. Sales, Practice Valuations/Appraisals Consulting, Placement.

CALIFORNIA MOUNTAIN PRACTICE in beautiful summer/winter resort area. Large lake and skiing areas. Can be part or full time, General or Internal Medicine. Next to small, innovative hospital. (916) 258-4203.

SEATTLE CHINATOWN—New medical office space available, air conditioned, complete lab. Best for bilingual Pediatrician, OBS-GYN, or another GP. Contact: Harry Lo, MD, 662 S. Jackson, Seattle, WA 98104 or (206) 622-4248.

INTERNAL MEDICINE PRACTICE FOR SALE IN SUNNY NEW MEXICO. Farming-ranching community of 30,000. Established, prestigious, gross over \$200,000. Physician going back into fellowship. Asking \$100,000 but willing to negotiate and finance. Close to fishing, skiing. Reply Box 6395, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

M-805—ORANGE COUNTY/SOUTHERN CALIFORNIA—Established, high-quality Internal Medicine practice. Office practice as well as hospital consultation. Grossed \$178,000 last year with an approximate 60% net to Doctor. Currently associated with five fine hospitals in area. Call Professional Practice Sales, Tustin, CA, (714) 832-0230.

EXCELLENT PRACTICE OPPORTUNITY for Board certified Family Practitioner in ideal San Francisco suburban community (East Bay). No OB. Dynamic and innovative Family Practice Group. Salary, bonus, fringes. Contact or send CV to Neal S. Fruman, MD, c/o Family and Urgent Care of Walnut Creek, 130 La Casa Via, Bldg. #2, Suite 108, Walnut Creek, CA 94598; (415) 930-8200.

INTERNAL MEDICINE: Retiring after thirty-five years. Gross \$200,000 plus. Will sell for price of complete office and laboratory \$25,000. Terms. Puget Sound area. Reply Box 6389, Western Journal of Medicine, 44 Gough St, San Francisco, CA 94103.

PRACTICES AVAILABLE

M-850—COLORADO, DENVER AREA—Established Family Practice. 4-day grossing \$120-130 K/year with nice net. Very well equipped including X-ray. Close to major hospital. Call Professional Practice Sales, Tustin, CA (714) 832-0230.

ACTIVE GENERAL PRACTICE available after first of year 1984. Established 36 years, retiring. Location Stockton, California. Write Box 6394, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

LOCUM TENENS

SUN VALLEY, IDAHO—LOCUM TENENS RADIOLOGIST needed for occasional coverage of low-volume practice. Plenty of time for daily enjoyment of skiing, golf, hiking or other varied activities. Superb opportunity to combine some work and some play. Contact R. Dennis Davis, MD, P.O. Box 242, Sun Valley, ID. (208) 622-3323 ext. 65.

LOCUM TENENS SERVICE WESTERN PHYSICIANS REGISTRY

... offers coverage for vacation or continuing education. To arrange coverage for your practice or to participate as temporary physician, contact: Carol Sweig, Director, 1124 Ballena, Alameda, CA 94501; (415) 521-4110.

LEGAL COUNSEL

BMQA

Former Deputy Atty. General representing BMQA & Dept. of Health. Now specializing in BMQA investigations and disciplinary actions. Hospital Staff Privilege cases and Defense Malpractice cases thruout Calif.

LAWS OFFICES OF SAMUEL E. SPITAL, A PROFESSIONAL CORP.
1200 THIRD AVE., #1200, SAN DIEGO, CA 92101 (619) 231-4848

OFFICE SPACE FOR RENT OR LEASE

CASTRO VALLEY, CALIFORNIA—Grove Way Medical Center near Eden Hospital. Available now—Two suites set-up for two doctors or group practice. 1,400-1,700 sq. ft. or will divide. Fully serviced building, Pharmacy, Lab and X-ray on premises. \$1.00 per sq. ft. includes all services and utilities. Call (415) 428-0823 or (415) 932-5197.

OFFICE SPACE FOR RENT OR LEASE

KENT, WASHINGTON—Prime space in established clinic in rapidly growing area. Near Valley General Hospital. \$0.625 per sq. ft. Free rent while establishing in this area. Call eves. (206) 246-0885.

OFFICE SPACE AVAILABLE

Castro Valley, California

THE GROVE WAY MEDICAL CENTER

800 to 1,600 sq. ft. Suites. Some set-up for two-man or group practices. FULLY SERVICED building, Pharmacy, Lab and X-ray on premises. \$1.00 sq. ft.

Call 428-0823 or 932-5197

MEDICAL EQUIPMENT WANTED

TAX DEDUCTIBLE DONATIONS of medical equipment and supplies urgently needed by the Central American Medical Relief Fund. Medical texts, journals, and other contributions also welcome. 1827 Haight St., Box 5, San Francisco, CA 94117 or call (415) 821-6471.

MEDICAL EQUIPMENT FOR SALE

ALPHA-STIM like new, take over lease, 12 months to go. Call (213) 995-4233.

CLASSIFIED
INFORMATION
(415) 863-5522
EXTENSION 244

PLEASE
NOTE
OUR NEW
PHONE NUMBER
AND
ADDRESS

**The Western
Journal of Medicine**

44 Gough Street
San Francisco, CA 94103

THE WESTERN JOURNAL OF MEDICINE

INFORMATION FOR AUTHORS

Submitting Manuscripts

Manuscripts for consideration should be sent to the editor, Malcolm S. M. Watts, MD, 44 Gough Street, San Francisco, California 94103. The transmittal letter should designate one person as correspondent and include complete address, with ZIP code and telephone number.

In view of *The Copyright Revision Act of 1976*, transmittal letters should contain the following language: "In consideration for reviewing and editing my submission, the author(s) undersigned hereby transfers, assigns or otherwise conveys all copyright ownership to THE WESTERN JOURNAL OF MEDICINE in the event that such work is published by the journal." This statement should be signed by *all* the authors.

Authors are urged to seek clarity and succinctness in all manuscripts regardless of subject matter or format and to give close attention to syntax, grammar and spelling.

Clinical Investigation Section

Articles that authors wish to have considered for the Clinical Investigation section should be so designated in the transmittal letter. The type of articles appropriate for this section are those that describe experimental work in humans that extensively and prospectively examines scientific hypotheses relating to disease. An article describing a single case report will not normally be considered appropriate for this section.

Preparing Manuscripts

The original manuscript and *two* copies should be submitted on heavy bond paper (8½ by 11 inches, *not* erasable), typed *double-spaced throughout* (including legends, tables and references) on one side of the paper, with 1½-inch margins. Ordinarily, articles should not exceed 3,000 words (less than 15 text pages, typed double-spaced). Under exceptional circumstances only will articles longer than 4,000 words be published. Pages should be numbered consecutively, beginning with the title page.

Style

Abbreviations. Use of abbreviations should be minimized. If they are necessary, abbreviations should be spelled out at first mention, with the abbreviation itself immediately following in parentheses.

Weights and measures. All measurements should be given in metric units. English equivalents should be given parenthetically if the measurements were originally done in English units.

Temperatures. Temperature readings should be given first in Celsius, followed by the Fahrenheit equivalent in parentheses.

Drug names. If the trade name of a drug is used, the generic name should be given first, followed by the trade name in parentheses. Trade names are capitalized, generic names are not.

Title Page

Titles are best when brief and concise. The title page should include the full name of the author(s), with degrees, academic or professional titles, complete addresses and any institutional or other affiliations. The complete name and address of the person who will handle reprint requests also should appear on this page.

Abstract

The abstract (approximately 150 words) should be a short summary, saying in brief what is said at length in the body of the article—rather than such and such "is discussed," "is presented" or "was investigated."

Tables and Figures

Tables

Each table should be typed on a separate sheet of paper, be numbered consecutively in Arabic numerals, have a brief descriptive title and have its position indicated in the text.

Illustrations (Figures)

Three sets of clear, unmounted black and white glossy prints of figures should be submitted (preferably 5 by 7 inches, but no larger than 8½ by 11 inches). For line drawings, original artwork or glossy prints are acceptable. Illustrations should be numbered consecutively in Arabic numerals and their position indicated in the text. Figure number, first author's name and top of the photo should be shown on the reverse side of each illustration. Recognizable photographs of patients are to be masked and written permission for publication obtained from the patients.

Legends

All legends for figures should be typed together on a separate sheet of paper. Magnification and stain for photomicrographs should be indicated in parentheses.

Permission for Reproduction

If an illustration or table has been used previously in another publication, written permission for its use must be obtained from the publisher, and should accompany the manuscript. The source should be acknowledged in the legend if it can be done

briefly by citation of a reference number. Otherwise, acknowledgment is made at the end of the figure legend or at the bottom of the table.

References

References should be limited to those cited in the text. They must be typed double-spaced and numbered consecutively as they appear in the manuscript. (See examples below for style.) Abbreviations of journal titles should conform to those used in *Index Medicus*.

Journal Articles

Note handling of multiple authorship. If more than three authors are listed as contributors, use "et al" to designate those names after the first three. Also note capitalization, punctuation, mention of inclusive page numbers, and month and year of publication. Separate the subtitle from the title by either a dash or a colon. Use colon *only* if it appears in the original citation.

1. Jones JS, Andersen HW, Johnson DW, et al: The athletic heart revisited—Sudden death of a 28-year-old athlete. *JAMA* 1978 Apr 26; 292:444-456

2. Graybill JR, Alford RH, Smith RG, et al: Cell-mediated immunity in cryptococcosis: A brief review. *Cell Immunol* 1978 Sep; 7:76-79

Books

Note handling of "edition," "editor(s)," and "volume," as well as appropriate sequence of reference information and capitalization of chapters and titles.

3. Berne EJ, Smith TL: Role playing in therapy, chap 2, *Principles of Group Therapy*. New York, Oxford University Press, 1966, pp 35-51 (*author of chapter same as author of book*)

4. Munsung JM: The role of drugs, chap 2, *In* Brest AN, Mayer JH (Eds): *Hypertension—Vol 2, Therapy*, 2nd Ed. Springfield, Ill, Charles C Thomas, 1961, pp 456-479 (*author of chapter different from authors of book*)

Pamphlets, Monographs or Books With No Given Author

5. AMA Department of Drugs: *AMA Drug Evaluation*, 3rd Ed. Littleton, Mass, Publishing Sciences Group, 1977 (*corporate author*)

6. *Compilation of Standard Definitions*, 3rd Ed. Philadelphia, American Society for Testing and Materials, 1976 (*no given author; give name and place of publisher*)

Articles in Press or Accepted for Publication

Any article accepted for publication should include the name of the journal (appropriately abbreviated) in which it will appear, and the phrase "in press" or "accepted for publication" in place of the date of publication.

Personal Communications and Unpublished Data

This information should *not* be included in the reference list but should be given in parentheses in the body of the text. Date of communication, whether it was personal or written, and the person's name, highest academic degree and professional affiliation should be provided.

Acknowledgments

It is the policy of the *WJM* not to print acknowledgments, the feeling being that if a person has contributed enough to a paper to be mentioned, he or she should be included among the authors, or the contribution should be mentioned in the body of the paper or in a footnote.

Correspondence

Brief manuscripts commenting on articles that have appeared in the journal, containing information of interest to physicians or discussing issues of the day will be considered for publication. Very short reports of cases, clinical experience, clinical studies, adverse effects and the like also will be considered. Items for the Correspondence section should not exceed 600 words and should have no more than five bibliographic references and one figure or table.

Author Responsibility

Authors are responsible for all statements made in articles. Manuscripts are considered for publication with the explicit understanding that they are original, have not been published previously and are not simultaneously under consideration by any other publication.

All accepted manuscripts are subject to copy editing, and authors are sent edited galley proofs for approval. No changes will be made after the final, edited version has been approved by the author.

Reprints

If reprints are desired, they must be paid for by the author. A reprint order form with schedule of prices is sent to the author when the article is published. Authors are responsible for handling requests for reprints of their articles.

RU-TUSS® II

sustained release capsules

Before prescribing, see complete prescribing information. The following is a brief summary.

DESCRIPTION: Each sustained release capsule contains 12 mg of Chlorpheniramine Maleate, USP and 75 mg of Phenylpropanolamine Hydrochloride, USP in a base to provide prolonged activity.

INDICATIONS: For the treatment of the symptoms of seasonal and perennial allergic rhinitis and vasomotor rhinitis, including nasal obstruction (congestion).

CONTRAINDICATIONS: Hypersensitivity to any of the components, concurrent MAO inhibitor therapy, severe hypertension, bronchial asthma, coronary artery disease, stenosing peptic ulcer, pyloroduodenal or bladder neck obstruction. Do not use in children under 12 years.

Do not use this drug in patients with narrow-angle glaucoma, obstructive or paralytic ileus, intestinal atony of the elderly or debilitated patient, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis. Do not use in nursing mothers.

Use in treating lower respiratory tract symptoms, including asthma, is contraindicated.

WARNINGS: Caution patients about activities requiring alertness (e.g., operating vehicles or machinery). Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients. Patients should also be warned about the possible additive effects of alcohol and other CNS depressants.

Usage in pregnancy: Safe use in pregnancy has not been established. Use only when the potential benefits have been weighed against the possible hazards to the mother and child. Note that an inhibitory effect on lactation may occur.

PRECAUTIONS: Use with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension, hiatal hernia with reflux esophagitis, intestinal atony of the elderly or debilitated intestinal obstruction, myasthenia gravis, renal function impairment, and ulcerative colitis (severe).

Drug Interactions: MAO inhibitors, Alcohol or CNS depressants, especially anesthetics, barbiturates, and narcotics.

ADVERSE REACTIONS: Prolongs the response to nervous stimulation, potentiates the response to norepinephrine, and inhibits the response to tyramine.

Slight to moderate drowsiness occurs relatively infrequently with Chlorpheniramine Maleate. Other possible side effects common in antihistamines in general include perspiration, chills, dryness of mouth, nose and throat.

Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles.

Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

Nervous System: Sedation, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteresis, neuritis, convulsions.

Gastrointestinal System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.

Genitourinary System: Urinary frequency, difficult urination, urinary retention, early menses.

Respiratory System: Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

DOSAGE AND ADMINISTRATION: Dosage should be individualized according to the needs and response of the patient. Adults: one capsule every 8 to 12 hours not to exceed 3 capsules daily. Not for use in children under 12 years of age.

OVERDOSAGE: Treatment of the signs and symptoms of overdosage is symptomatic and supportive. In the event of overdosage, emergency treatment should be started immediately.

Treatment: The patient should be induced to vomit, even if emesis has occurred spontaneously. Vomiting by the administration of ipecac syrup is a preferred method. However, vomiting should not be induced in patients with impaired consciousness. Stimulants (analeptic agents) should not be used. Vasopressors may be used to treat hypotension. Short-acting barbiturates, diazepam or paraldehyde may be administered to control seizures. Hyperpyrexia, especially in children, may require treatment with tepid water sponge baths or a hypothermic blanket. Apnea is treated with ventilatory support.

HOW SUPPLIED: Green and clear capsules with green and white beads. Bottles of 100 tablets. NDC 0524-0031-01

Store at controlled room temperature 15-30°C (59°-86°F).

CAUTION: Federal law prohibits dispensing without prescription.

Distributed By
Boots Pharmaceuticals, Inc.
Shreveport, LA 71106

Manufactured By
Cord Laboratories, Inc.
Broomfield, CO 80020



Boots Pharmaceuticals, Inc.
Shreveport, LA 71106
Pioneers in medicine for the family

(Continued from Page 644)

Fourth Monday—8-9 a.m. Contact: Howard Berk, MD, (801) 364-4438.

MONTHLY OPHTHALMOLOGY FLUORESCIN ANGIOGRAPHY CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Fourth Monday—7:30-8:30 a.m. Contact: Roy Goodart, MD, (801) 532-7406 or F. T. Reikhof, MD, (801) 532-7406.

INTERDEPARTMENTAL GRAND ROUNDS

Utah Valley Hospital, Provo, 1034 North Fifth West, Provo 84601.

Contact: Gary Watts, MD, UVH, 1034 North Fifth West, Provo, UT 84601. (801) 373-7850 (Ext 2143).

* * * *

January 13-14—**Conference on Spina Bifida** (Sponsor: University of Utah/Primary Children's Hospital. Friday-Saturday. Airport Hilton, Salt Lake City. 12 hrs. \$100, physicians; \$75, allied health professionals. Contact: Paula Peterson, (801) 363-1221, ext. 200.

January 25-28—**27th Midwinter Conference on Chest Disease** (Sponsor: Intermountain Thoracic Society). Wednesday-Saturday. Snowbird. \$170. Contact: Frank Brough, PhD, (801) 484-4456.

January 27-29—**8th Annual University of Utah Seminar on Sexual Function/Dysfunction**. Friday-Sunday. Yarrow/Holiday Inn, Park City. Contact: Don Strassberg, PhD, (801) 581-5809.

February 1-3—**Common Problems in Pediatrics** (Sponsor: University of Utah). Sunday-Tuesday. Salt Lake City. 13 hrs. Fee to be announced. Contact: Wendy Ellis, (801) 581-3573.

February 8-11—**Practical Neurology for Clinicians** (Sponsor: University of Utah). Wednesday-Saturday. Hotel Utah, Salt Lake City. 22 hrs. Fee to be announced. Contact: J. Richard Baringer, MD, (801) 581-8664.

(Continued on Page 762)

SPONSORS OF COURSES—ABBREVIATIONS

AF:	Arthritis Foundation, 1174 East 2700 South, Salt Lake City 84117. (801) 466-9389.
CH:	Castleview Hospital (formerly Carbon Hospital), RFD 2, Box 46, Price, UT 84501. (801) 637-4800.
CWH:	Cottonwood Hospital, 5770 South 300 East, Salt Lake City 84101. (801) 262-3461.
FHP:	Family Health Program/Utah, 323 South Sixth East, Salt Lake City 84102. (801) 335-1234. Contact: Kay Schultz for course information.
HAFB:	Hill Air Force Hospital, Hill Air Force Base 84406. (801) 777-1262.
HCH:	Holy Cross Hospital, 1045 East First South, Salt Lake City 84102. (801) 350-4744.
LDSH:	Latter-Day Saints Hospital, 325 8th Avenue, Salt Lake City 84143. (801) 350-1100.
MDH:	McKay-Dee Hospital Center, 3939 Harrison Blvd., Ogden 84409. (801) 399-4141.
OEH:	Rocky Mountain Center for Occupational and Environmental Health, 50 North Medical Drive, Salt Lake City 84132. (801) 581-8719.
OSS:	Ogden Surgical Society, PO Box 9311, Ogden 84409.
PCMC:	Primary Children's Medical Center, 320 12th Ave., Salt Lake City 84103. (801) 363-1221.
SHCC:	Shriners Hospital for Crippled Children, Intermountain Unit, Fairfax Ave. at Virginia St., Salt Lake City 84103. (801) 532-5307.
SLSC:	Salt Lake Surgical Center, 617 East 3900 South, Salt Lake City 84117. (801) 261-3141.
UAFF:	Utah Academy of Family Physicians, 1146 Westminster Ave., Salt Lake City 84105. (801) 466-9478.
UUMC:	University of Utah Medical Center, 50 North Medical Drive, Salt Lake City 84132. (801) 581-2258.
USMA:	Utah State Medical Association, 540 East Fifth South, Salt Lake City 84102. (801) 355-7477.
UVH:	Utah Valley Hospital, 1034 North Fifth West, Provo 84601. (801) 373-7850.
VAMC:	Veterans Administration Medical Center, 500 Foothill Drive, Salt Lake City 84148. (801) 582-1565.

Motrin® Tablets (ibuprofen)

Contraindications: Anaphylactoid reactions have occurred in individuals hypersensitive to Motrin Tablets or with the syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin, iodides, or other nonsteroidal anti-inflammatory agents.

Warnings: Peptic ulceration and GI bleeding, sometimes severe, have been reported. Ulceration, perforation and bleeding may end fatally. An association has not been established. Use Motrin Tablets under close supervision in patients with a history of upper gastrointestinal tract disease, after consulting ADVERSE REACTIONS. In patients with active peptic ulcer and active rheumatoid arthritis, try nonulcerogenic drugs, such as gold. If Motrin Tablets are used, observe the patient closely for signs of ulcer perforation or GI bleeding.

Chronic studies in rats and monkeys have shown mild renal toxicity with papillary edema and necrosis. Renal papillary necrosis has rarely been shown in humans treated with Motrin Tablets.

Precautions: Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported. If these develop, discontinue Motrin Tablets and the patient should have an ophthalmologic examination, including central visual fields and color vision testing.

Fluid retention and edema have been associated with Motrin Tablets; use with caution in patients with a history of cardiac decompensation or hypertension. In patients with renal impairment, reduced dosage may be necessary. Prospective studies of Motrin Tablets safety in patients with chronic renal failure have not been done.

Motrin Tablets can inhibit platelet aggregation and prolong bleeding time. Use with caution in persons with intrinsic coagulation defects and on anticoagulant therapy.

Patients should report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

Patients on prolonged corticosteroid therapy should have therapy tapered slowly when Motrin Tablets are added.

The antipyretic, anti-inflammatory activity of Motrin Tablets may mask inflammation and fever.

As with other nonsteroidal anti-inflammatory drugs, borderline elevations of liver tests may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. Meaningful elevations of SGPT or SGOT (AST) occurred in controlled clinical trials in less than 1% of patients. Severe hepatic reactions, including jaundice and cases of fatal hepatitis, have been reported with ibuprofen as with other nonsteroidal anti-inflammatory drugs. If liver disease develops or if systemic manifestations occur (e.g. eosinophilia, rash, etc.), Motrin should be discontinued.

Drug interactions: Aspirin: used concomitantly may decrease Motrin blood levels.

Coumarin: bleeding has been reported in patients taking Motrin and coumarin.

Pregnancy and nursing mothers: Motrin should not be taken during pregnancy or by nursing mothers.

Adverse Reactions: The most frequent type of adverse reaction occurring with Motrin is gastrointestinal of which one or more occurred in 4% to 16% of the patients.

Incidence Greater than 1% (but less than 3%)—Probable Causal Relationship

Gastrointestinal: Nausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of GI tract (bloating and flatulence); **Central Nervous System:** Dizziness*, headache, nervousness; **Dermatologic:** Rash* (including maculopapular type), pruritus; **Special Senses:** Tinnitus; **Metabolic/Endocrine:** Decreased appetite; **Cardiovascular:** Edema, fluid retention (generally responds promptly to drug discontinuation; see PRECAUTIONS).

Incidence less than 1%—Probable Causal Relationship**

Gastrointestinal: Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; **Central Nervous System:** Depression, insomnia, confusion, emotional lability, somnolence, aseptic meningitis with fever and coma; **Dermatologic:** Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia; **Special Senses:** Hearing loss, amblyopia (blurred and/or diminished vision, scotomata, and/or changes in color vision) (see PRECAUTIONS); **Hematologic:** Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit; **Cardiovascular:** Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations; **Allergic:** Syndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm (see CONTRAINDICATIONS); **Renal:** Acute renal failure in patients with pre-existing significantly impaired renal function, decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria; **Miscellaneous:** Dry eyes and mouth, gingival ulcer, rhinitis.

Incidence less than 1%—Causal Relationship Unknown**

Gastrointestinal: Pancreatitis; **Central Nervous System:** Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri; **Dermatologic:** Toxic epidermal necrolysis, photoallergic skin reactions; **Special Senses:** Conjunctivitis, diplopia, optic neuritis; **Hematologic:** Bleeding episodes (e.g., epistaxis, menorrhagia); **Metabolic/Endocrine:** Gynecomastia, hypoglycemic reaction; **Cardiovascular:** Arrhythmias (sinus tachycardia, sinus bradycardia); **Allergic:** Serum sickness, lupus erythematosus syndrome, Henoch-Schönlein vasculitis; **Renal:** Renal papillary necrosis.

*Reactions occurring in 3% to 9% of patients treated with Motrin. (Those reactions occurring in less than 3% of the patients are unmarked.)

**Reactions are classified under "Probable Causal Relationship (PCR)" if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under "Causal Relationship Unknown" if seven or more events have been reported but the criteria for PCR have not been met.

Overdosage: In cases of acute overdosage, the stomach should be emptied. The drug is acidic and excreted in the urine so alkaline diuresis may be beneficial.

Dosage and Administration: Rheumatoid arthritis and osteoarthritis. Suggested dosage is 300, 400, or 600 mg t.i.d. or q.i.d. Do not exceed 2400 mg per day. Mild to moderate pain: 400 mg every 4 to 6 hours as necessary.

Caution: Federal law prohibits dispensing without prescription.

Motrin is a registered trademark of The Upjohn Manufacturing Company M, Barceloneta, Puerto Rico

MED B-7-S

Upjohn

J-3255

September 1983

February 13-16—13th Annual Family Practice Refresher Course (Sponsor: University of Utah). Monday-Thursday. Salt Lake City Hilton. 28 hrs. Fee to be announced. Contact: Linda Twitchell, (801) 581-8633.

February 17-21—29th Annual Postgrad Course in Anesthesiology (Sponsor: University of Utah). Friday-Tuesday. Salt Lake City. 16 hrs. Fee to be announced. Contact: K. C. Wong, MD, (801) 581-6115.

February 18-22—25th Annual OB/GYN Update (Sponsor: University of Utah). Saturday-Wednesday. Park City, 14½ hrs. Fee to be announced. Contact: James Scott, MD, (801) 581-5501.

February 22-25—Gynecologic Oncology Update (Sponsor: University of Utah). Wednesday-Saturday. Park City. 14½ hrs. Fee to be announced. Contact: James Scott, MD, (801) 581-5501.

February 27-March 2—3rd Annual Park City Dermatology Seminar (Sponsor: University of Utah). Monday-Thursday. Park City Yarrow (Holiday Inn). 18 hrs. Fee to be announced. Contact: Gerald Krueger, MD, (801) 581-7837.

Note: Dates, times, places and programs are subject to change on occasion. Please check with the sponsoring organization or the Academy for details.

WASHINGTON

This listing of continuing medical education programs in Washington state is compiled by the Washington State Medical Association. To list Category 1 programs here please send information at least two months in advance to Continuing Medical Education, Washington State Medical Association, 2033 Sixth Avenue, Suite 900, Seattle, WA 98121; or phone (206) 623-4801.

Brochures and Registration Forms are available from the contact person or organization listed at the end of each course or in the course sponsors and contact information box.

November 17-18—Infectious Diseases. Seattle. Thursday-Friday. The Park Hilton. Contact: Marilyn Carlson, Secretary, Education and Training Department, Northwest Hospital, 1550 N. 115th Street, Seattle 98133. (206) 364-0500, ext. 1737.

November 17-18—Topics in Emergency Medicine. Seattle. Thursday-Friday. SeaTac Marriott. Contact: Washington ACEP, Heidi Hilby, Executive Secretary, 2033 Sixth Avenue, Suite 900, Seattle, WA 98121. (206) 623-4801.

November 18—Frontiers of Immunobiology. Seattle. Friday. Virginia Mason Hospital Auditorium. Contact: VMMC.

November 18-19—Diabetes: A New Era in Management. Seattle. Friday-Saturday. Madison Hotel. Contact: U/W.

November 19—Radiology Northwest. Seattle. Saturday. U/W CDMRC. Contact: U/W.

November 19-26—(HAWAII) Ethical Issues in Clinical Medicine. Maui. Saturday-Saturday. Intercontinental Hotel. Contact: U/W.

December 2-3—Aging and Elderly. Seattle. Friday-Saturday. Westin Hotel. Contact: U/W.

December 2-3—Legal Aspects of Toxicology. Seattle. Friday-Saturday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

December 2-4—Washington State Society of Anesthesiologists/Canadian Anaesthetists' Society. Seattle. Friday-Saturday. Four Seasons Hotel. Contact: WSSA, Patti Smith, Executive Secretary, 2033 Sixth Avenue, Suite 900, Seattle 98121. (206) 623-4801.

(Continued on Page 766)

**OR TO GIVE
TO RECEIVE**

A circular arrangement of the letters 'wjm' repeated multiple times in a cursive script, forming a spiral pattern. The letters are written in a dark, flowing cursive style, with the 'w' and 'j' being particularly prominent. The arrangement starts from the top left and spirals outwards, creating a sense of continuous motion and repetition. The background is plain white, which makes the dark cursive letters stand out. The overall effect is a visually engaging and rhythmic composition.

763

Diet & Diabinese®

(chlorpropamide) Tablets
100 mg and 250 mg

**A proven regimen
for effective control
of blood sugar.**

BRIEF SUMMARY

DIABINESE® (chlorpropamide) Tablets

Contraindications: Diabinese is not indicated in patients having juvenile or growth-onset diabetes mellitus, severe or unstable "brittle" diabetes, and diabetes complicated by ketosis and acidosis, diabetic coma, major surgery, severe infection, or severe trauma. Diabinese is contraindicated during pregnancy. Serious consideration should be given to the potential hazard of its use in women of childbearing age who may become pregnant.

Diabinese is contraindicated in patients with serious impairment of hepatic, renal, or thyroid function.

Precautions: Use chlorpropamide with caution with barbiturates, in patients with Addison's disease or in those ingesting: alcohol, antibacterial sulfonamides, thiazides, phenylbutazone, salicylates, probenecid, dicoumarol or MAO inhibitors. Adequate dietary intake should be assured in all patients using Diabinese.

Warnings: DIABINESE (CHLORPROPAMIDE) SHOULD NOT BE USED IN JUVENILE DIABETES OR IN DIABETES COMPLICATED BY ACIDOSIS, COMA, SEVERE INFECTION, MAJOR SURGICAL PROCEDURES, SEVERE TRAUMA, SEVERE DIARRHEA, NAUSEA AND VOMITING, ETC. HERE, INSULIN IS INDISPENSABLE.

HYPOGLYCEMIA, IF IT OCCURS, MAY BE PROLONGED. (SEE ADVERSE REACTIONS.) IN INSTANCES OF CONCOMITANT USE WITH INSULIN, PATIENTS SHOULD BE CAREFULLY MONITORED.

Adverse Reactions: Usually dose-related and generally respond to reduction or withdrawal of therapy. Generally transient and not of a serious nature and include anorexia, nausea, vomiting and gastrointestinal intolerance; weakness and paresthesias.

Certain untoward reactions associated with idiosyncrasy or hypersensitivity have occasionally occurred, including jaundice, skin eruptions rarely progressing to erythema multiforme and exfoliative dermatitis, and probably depression of formed elements of the blood. They occur characteristically during the first six weeks of therapy. With a few exceptions, these manifestations have been mild and readily reversible on the withdrawal of the drug. The more severe manifestations may require other therapeutic measures, including corticosteroid therapy. Diabinese should be discontinued promptly when the development of sensitivity is suspected.

Jaundice has been reported, and is usually promptly reversible on discontinuance of therapy. THE OCCURRENCE OF PROGRESSIVE ALKALINE PHOSPHATASE ELEVATION SHOULD SUGGEST THE POSSIBILITY OF INCIPENT JAUNDICE AND CONSTITUTES AN INDICATION FOR WITHDRAWAL OF THE DRUG. Leukopenia, thrombocytopenia and mild anemia, which occur occasionally, are generally benign and revert to normal, following cessation of the drug.

Cases of aplastic anemia and agranulocytosis, generally similar to blood dyscrasias associated with other sulfonylureas, have been reported.

BECAUSE OF THE PROLONGED HYPOGLYCEMIC ACTION OF DIABINESE, PATIENTS WHO BECOME HYPOGLYCEMIC DURING THERAPY WITH THIS DRUG REQUIRE CLOSE SUPERVISION FOR A MINIMUM PERIOD OF 3 TO 5 DAYS, during which time frequent feedings or glucose administration are essential. The anorectic patient or the profoundly hypoglycemic patient should be hospitalized.

Rare cases of phototoxic reactions have been reported. Edema associated with hyponatremia has been infrequently reported. It is usually readily reversible when medication is discontinued.

Dosage: The total daily dosage is generally taken at a single time each morning with breakfast. Occasionally, cases of gastrointestinal intolerance may be relieved by dividing the daily dosage. A LOADING OR PRIMING DOSE IS NOT NECESSARY AND SHOULD NOT BE USED. The mild to moderately severe, middle-aged, stable diabetic should be started on 250 mg daily. Because the geriatric diabetic patient appears to be more sensitive to the hypoglycemic effect of sulfonylurea drugs, older patients should be started on smaller amounts of Diabinese, in the range of 100 to 125 mg daily.

After five to seven days following initiation of therapy, dosage may be adjusted upward or downward in increments of 50 to 125 mg at intervals of three to five days. PATIENTS WHO DO NOT RESPOND COMPLETELY TO 500 MG DAILY WILL USUALLY NOT RESPOND TO HIGHER DOSES. Maintenance doses above 750 mg daily should be avoided.

Supply: 100 mg and 250 mg, blue, 'D'-shaped, scored tablets.

More detailed professional information available on request.

Pfizer LABORATORIES DIVISION
PFIZER INC.

Leaders in Oral Diabetic Therapy

(Continued from Page 762)

December 3—**Endocrinology Day.** Seattle. Saturday. U/W CDMRC. Contact: U/W.

December 3—**Psychiatry for Attorneys.** Seattle. Saturday. U/W Health Sciences Building. Contact: U/W.

December 8-9—**Surgery and Strauss Lecture.** Seattle. Friday-Saturday. Westin Hotel. Contact: U/W.

December 9—**Practical Pediatrics, 1983.** Seattle. Friday. Virginia Mason Hospital Auditorium. Contact: VMMC.

December 9-10—**Internal Medicine.** Seattle. Friday-Saturday. U/W South Campus Center. Contact: U/W.

December 10—**Radiology Northwest.** Seattle. Saturday. U/W CDMRC. Contact: U/W.

January 12—**Imaging Update: Devices and Modalities.** Seattle. Thursday. Ballard Community Hospital. Contact: U/W.

January 12—**Industrial Hearing Conservation Workshop.** Seattle. Thursday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

January 13-14—**Arthritis Symposium.** Seattle. Friday-Saturday. Virginia Mason Hospital Auditorium. Contact: VMMC.

January 19-21—**Washington State Academy of Ophthalmology—1984 Annual President's Meeting.** Seattle. Thursday-Saturday. Sheraton Hotel. Contact: WSAO, Patti Smith, Executive Secretary, 2033 Sixth Avenue, Suite 900, Seattle 98121. (206) 623-4801.

January 20—**Gynecologic Surgery.** Seattle. Friday. Virginia Mason Hospital Auditorium. Contact: VMMC.

January 21—**Radiology Northwest.** Seattle. Saturday. U/W CDMRC. Contact: U/W.

January 25-26—**Welding and Painting Hazards.** Seattle. Wednesday-Thursday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

January 26-27—**Cardiology Update 1984.** Seattle. Thursday-Friday. Westin Hotel. Contact: U/W.

February 4-5—**Nutritional Support for the Hospitalized Patient.** Seattle. Saturday-Sunday. U/W Health Sciences Center. Contact: U/W.

February 9—**Management of Safety and Health Programs.** Seattle. Thursday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

February 10—**Stress and the Physician.** Seattle. Friday. Virginia Mason Hospital Auditorium. Contact: VMMC.

February 11-12—**Advanced Cardiac Life Support.** Seattle. Saturday-Sunday. U/W Health Sciences Center. Contact: U/W.

February 12-17—**(IDAHO) Sun Valley Primary Care Conference.** Sunday-Friday. The Lodge, Sun Valley. Contact: Marilyn Carlson, Secretary, Education and Training Department, Northwest Hospital, 1550 North 115th Street, Seattle 98133. (206) 364-0500, ext. 1737.

February 17-18—**Winter Clinical Symposium.** Wenatchee.

(Continued on Page 771)

COURSE SPONSORS AND CONTACT INFORMATION

CME HARBORVIEW—Contact: Gayle Splater, Cytology Continuing Education, Dept. of Pathology, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104. (206) 223-5953.

CME PIERCE COUNTY—Contact: Mrs. Maxine Bailey, Executive Director, College of Medical Education, 705 South Ninth, No. 203, Tacoma, WA 98405. (206) 627-7137.

U/W (UNIVERSITY OF WASHINGTON) — Contact: U/W School of Medicine, Div. of CME, SC-50, Seattle, WA 98195. (206) 543-1050.

VMMC (VIRGINIA MASON MEDICAL CENTER)—Contact: Linda Orgel, Division of Continuing Medical Education, Virginia Mason Medical Center, 1100 Ninth Avenue, P.O. Box 900, Seattle, WA 98101. (206) 223-6898.

Friday-Saturday. Thunderbird Motor Inn. Contact: Heidi Bush, Washington Chapter, ACEP, 2033 Sixth Ave, Suite 900, Seattle 98121. (206) 623-4801.

February 18—**Radiology Northwest**. Seattle. Saturday. U/W CDMRC. Contact: U/W.

February 18-25—(IDAHO) **Sports Medicine**. Sun Valley. One week. Contact: U/W.

February 23-24—**Respiratory Protection**. Seattle. Thursday-Friday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

February 24-25—**Child Psychiatry Update**. Seattle. Friday-Saturday. Children's Orthopedic Hospital. Contact: U/W.

February 24-25—**Revolutions in Laboratory Medicine and Pathology: What Clinicians Need to Know**. Seattle. Friday-Saturday. Virginia Mason Hospital Auditorium. Contact: VMMC.

February 25-26—**Nutritional Support of the Hospitalized Patient**. Seattle. Saturday-Sunday. U/W Health Sciences Center. Contact: U/W.

March 2—**Occupational Neurological Diseases**. Seattle. Friday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

March 3-10—(HAWAII) **Diagnosis and Drug Therapy**. Saturday-Saturday. Sheraton Royal Waikoloa, Island of Hawaii. Contact: U/W.

March 8—**Diabetes: Latest Concepts in Treatment**. Seattle. Thursday. Ballard Community Hospital. Contact: U/W.

March 9-10—**Hematology and Oncology**. Seattle. Friday-Saturday. Museum of History and Industry. Contact: U/W.

March 10-17—(HAWAII) **Financial Planning for Physicians**. Saturday-Saturday. Inter-Continental Hotel, Maui. Contact: U/W.

March 17—**Radiology Northwest**. Seattle. Saturday. U/W CDMRC. Contact: U/W.

March 17—**Office Lab Diagnosis for Clinicians**. Seattle. Saturday. U/W Health Sciences Center. Contact: U/W.

March 17-24—(HAWAII) **Obstetrics and Gynecology**. Saturday-Saturday. Kauai Sheraton, Kauai. Contact: U/W.

March 18-25—(HAWAII) **The Spine**. Sunday-Sunday. Westin Wailea Beach, Maui. Contact: U/W.

March 21-23—**Spirometry Training for Worker Screening**. Seattle. Wednesday-Thursday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

March 24-31—(HAWAII) **The Injured Patient: Controversies and Challenges**. Saturday-Saturday. Kauai Sheraton, Kauai. Contact: U/W.

March 29—**Pediatric Ophthalmology**. Seattle. Thursday. Children's Orthopedic Hospital. Contact: Patti Smith, Meeting Coordinator, Washington State Academy of Ophthalmology, 2033 Sixth Ave., Suite 900, Seattle 98121. (206) 623-4801.

March 31-April 7—(HAWAII) **High-Risk Infants and Adolescents**. Saturday-Saturday. Inter-Continental Hotel, Maui. Contact: U/W.

April 2-15—**Rehabilitation Medicine Review**. Seattle. Monday-Sunday. Sheraton Hotel. Contact: U/W.


April 4-6—**Introduction to Industrial Hygiene**. Seattle. Wednesday-Thursday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

April 6-7—**Infectious Diseases in Children**. Seattle. Friday-Saturday. Children's Orthopedic Hospital. Contact: U/W.

April 7-8—**Arrhythmias**. Seattle. Saturday-Sunday. U/W Health Sciences Center. Contact: U/W.

April 14-15—**Patient Safety in Anesthesia**. Seattle. Saturday-Sunday. Westin Hotel. Contact: Patti Smith, Executive Secretary, Washington State Society of Anesthesiologists, 2033 Sixth Ave., Suite 900, Seattle 98121. (206) 623-4801.

This Publication is available in Microform.



University Microfilms International

Please send additional information

for _____
(name of publication)

Name _____

Institution _____

Street _____

City _____

State _____ Zip _____

300 North Zeeb Road
Dept. P.R.
Ann Arbor, Mi. 48106

WESTERN STATE MEDICAL ASSOCIATIONS' MEETINGS

Alaska State Medical Association—4107 Laurel St., Anchorage 99504. (907) 277-6891. Annual Meeting: June 8-12, 1984, Valdez Convention Center.

Arizona Medical Association, Inc.—810 W. Bethany Home Rd., Phoenix 85013. (602) 246-8901. Annual Meeting: April 27-28, 1984, Scottsdale Conference Center, Scottsdale.

California Medical Association—44 Gough St., San Francisco 94103. (415) 863-5522. Annual Meeting: February 10-15, 1984, Disneyland Hotel, Anaheim.

Colorado Medical Society—6825 E. Tennessee, Bldg. 2, Suite 500, Denver 80224. (303) 321-8590. Annual Meeting: 1984—date and place to be announced.

Hawaii Medical Association—320 Ward Ave., Suite 200, Honolulu 96814. (808) 536-7702. Annual Meeting: 1984—date and place to be announced.

Idaho Medical Association—407 W. Bannock St., P.O. Box 2668, Boise 83701. (208) 344-7888. Annual Meeting: 1984—date and place to be announced.

Montana Medical Association—2012 11th Ave., Suite 12, Helena 59601. (406) 433-4000. Annual Meeting: 1984—date and place to be announced.

Nevada State Medical Association—3660 Baker Lane, Reno 89502. (702) 825-6788. Annual Meeting: May 3-6, 1984, Desert Inn, Las Vegas.

New Mexico Medical Society—303 San Mateo NE, Suite 204, Albuquerque 87108. (505) 266-7868. Annual Meeting: May 2-4, 1984, Santa Fe.

Oregon Medical Association—5210 S.W. Corbett Ave., Portland 97201. (503) 226-1555. Annual Scientific Session: November 3-4, 1983, Thunderbird, Jantzen Beach.

Utah State Medical Association—540 East Fifth South, Salt Lake City 84102. (801) 355-7477. Annual Meeting: 1984—date and place to be announced.

Washington State Medical Association—900 United Airlines Bldg., 2033 6th Ave., Seattle 98121. (206) 623-4801. Annual Meeting: 1984—date and place to be announced.

Wyoming Medical Society—P.O. Drawer 4009, Cheyenne 82003-4009. (307) 635-2424. Annual Meeting: June 24-28, 1984, Jackson Lake Lodge, Moran.

April 20-21—**Endocrine Day**. Union. Friday-Saturday. Alderbrook Inn. Contact: U/W.

April 21—**Radiology Northwest**. Seattle. Saturday. U/W CDMRC. Contact: U/W.

April 27-28—**Industrial Back Pain**. Seattle. Friday-Saturday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

April 28—**Medicine and Religion**. Seattle. Saturday. U/W CDMRC. Contact: U/W.

May 3-4—**Cancer Symposium**. Seattle. Thursday-Friday. Westin Hotel. Contact: U/W.

May 5-6—**Advanced Cardiac Life Support**. Seattle. Saturday-Sunday. U/W Health Sciences Center. Contact: U/W.

May 11-12—**Health Issues for Exercising Women**. Seattle. Friday-Saturday. U/W Health Sciences Center. Contact: U/W.

May 12-13—**Pharmacology for Anesthesiologists**. Seattle. Saturday-Sunday. U/W Health Sciences Center. Contact: U/W.

May 16-18—**Noise Measurement and Control**. Seattle. Wednesday-Thursday. Contact: Northwest Center for Occupational

ADVERTISING INDEX

AMERICAN MEDICAL ASSOCIATION	767
AYERST LABORATORIES	
Inderal/LA	612, 613, 614
BOOTS PHARMACEUTICALS CO.	
Ru-Tuss II	758, 759
BURROUGHS-WELLCOME CO.	
Zyloprim	604
CALIFORNIA MEDICAL ASSOC.	750, 751
CLASSIFIED	646, 648, 752, 754
CNA INSURANCE CO.	631
COOPERATIVE OF AMERICAN PHYSICIANS	603
CPS MEDICAL BILLING SYSTEMS	645
DOCTORS' COMPANY, THE	749
ELI LILLY & CO.	
Keflex	609
GLAXO INCORPORATED	
Zantax	755, 756
INSURANCE CORPORATION OF AMERICA	638, 639
KEY PHARMACEUTICALS, INC.	
Theo-Dur	634, 635, 636
NORCAL MUTUAL INSURANCE CO.	610
PFIZER LABORATORIES	
Diabinese	764, 765, 766
Feldene	615, 616, 617, 618
Procardia	632, 633
PHYSICIANS AND SURGEONS INSURANCE EXCHANGE	649
PRACTICE SERVICES CORPORATION	641
RCI COMPUTER SERVICE	601
ROCHE LABORATORIES, INC.	
Bactrim	2nd Cover, 599 and 600
Berocca Plus	629, 630
Dalmene	621, 622
Librax	624, 625
Valium	3rd and 4th Cover
SEARLE & CO.	
Theo-24	619, 620
SFC FINANCIAL SERVICES	647
SMITH KLINE & FRENCH LABORATORIES	
Dyazide	650
SOUTHERN CALIFORNIA PHYSICIANS INSURANCE EXCHANGE	623
E. R. SQUIBB & SONS	
Corgard	606, 607
UNIVERSITY MICROFILMS INTERNATIONAL	771
UNIVERSITY OF HAWAII SPORTS MEDICINE	600
UPJOHN COMPANY, THE	
Halcion	642, 643, 644
Motrin	760, 761, 762
Xanax	642, 643
US AIR FORCE RESERVES	753
WESTERN JOURNAL OF MEDICINE, THE	
Subscription Form	763
WYETH LABORATORIES	
LO/OVRAL	626, 627, 628

Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

May 19—**Radiology Northwest**. Seattle. Saturday. U/W CDMRC. Contact: U/W.

May 24-25—**Hereditary Diseases of the Nervous System**. Seattle. Thursday-Friday. Mayflower Park Plaza. Contact: U/W.

June 1-2—**Health Hazards in the Modern Office**. Seattle. Friday-Saturday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

June 14-15—**Use of Microcomputers in Occupational Safety and Health**. Seattle. Thursday-Friday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.

July 12-13—**Second Annual Conference on Occupational Hazards to Health Care Workers**. Seattle. Thursday-Friday. Contact: Northwest Center for Occupational Health and Safety, Department of Environmental Health, SC-34, University of Washington, Seattle 98195. (206) 543-1069.